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1 Introduction 
1.1 RNA interference 
The phenomenon of gene silencing was initially described in plants. It was discovered 
that the introduction of an additional gene in plants (a transgene) not only induced gene 
expression but could also inhibit the expression of homologous sequences. This 
inhibition could either take place at the level of transcription (transcriptional gene 
silencing, TGS) or at the posttranscriptional level (posttranscriptional gene silencing, 
PTGS) (1-3). A process similar to PTGS called quelling was also observed in the fungus 
Neurospora crassa (4). However the exact mechanism of these phenomenons remained 
unclear.  
In 1998 Andrew Fire and Craig Mello published their breakthrough study about the 
mechanism of RNA interference (5). They could demonstrate that injection of long 
double stranded RNA (dsRNA) into the nematode C. elegans sequence specifically 
induced silencing of homologous genes. In a follow up study they provided good 
evidence that mRNA is the target for dsRNA induced gene silencing and that the 
mRNA is degraded prior to translation (6). Finally it became clear that 
posttranscriptional gene silencing in plants and RNA interference are fundamentally 
related processes both mediated by double stranded RNA molecules (7-9).  
Soon after these discoveries the occurrence of RNA interference (RNAi) was 
documented in various organisms ranging from fruit fly to zebrafish (10). Biochemical 
studies showed that target mRNA degradation is guided by 21-23 nucleotide (nt) long 
double stranded RNAs that are fragments of long double stranded precursor RNAs 
(11,12). In accordance to these findings Elbashir et al. were able to elicit a potent and 
specific RNAi response in cultured mammalian cells by the application of short (21-23 
nt) double stranded RNAs so called short interfering RNAs (siRNAs) without the 
induction of unspecific interferon-linked pathways (9). This was the starting point for 
the rapid development of RNA interference to a standard laboratory research tool. 
Another class of endogenous small (19-25 nt), non coding RNAs are the so called 
microRNAs (miRNAs) that mediate gene regulation in widespread processes e.g. 
development, proliferation or apoptosis (13). They are also recognized and processed by 
the endogenous RNAi machinery but in contrast to siRNAs they induce gene silencing 
by the suppression of mRNA translation. A third less well understood pathway of gene 
regulation that is mediated by small dsRNA effector molecules leads to gene silencing 
through heterochromatin methylation (reviewed by Lippman) (14).  
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RNA interference can be triggered by various sources of RNA like RNA viruses, 
transposons or exogenously introduced RNA like long dsRNA or siRNA.  
 
Fig. 1.1: Scheme of the basic mechanism of RNA interference in humans. In the initial step long dsRNAs 
are cleaved by an RNase II-type enzyme called Dicer into 21-23 nt long siRNA molecules. The processed 
siRNAs are bound and unwound by a multi protein complex RISC. The antisense strand of the siRNA is 
assembled into the activated effector complex siRISC. Complementary mRNA sequences are recognized 
by siRNA antisense mRNA base pairing and cleaved by the endonuclease activity of RISC. After 
cleavage product release siRISC can enter a new cycle of mRNA recognition and cleavage. Picture taken 
from ref (15). 
 
The initial step of the RNA interference pathway is the processing of long dsRNA by an 
RNase III-type enzyme called Dicer (16). It has been shown that Dicer accepts both 
linear dsRNA and hairpin dsRNA as substrates. Thus it is possible to achieve gene 
silencing by the expression of short hairpin RNAs from DNA vectors (17). Dicer 
cleavage products are 21 to 23 nt long siRNAs that contain 2 nt overhangs at their 3’ 
end and a 5’ phosphate group. Dicer processing is not necessary for the induction of 
RNA interference since the introduction of post Dicer cleavage products such as 
synthetic siRNAs, also elicits gene silencing. However several publications have 
demonstrated that the introduction of DICER substrate dsRNA can lead to more potent 
gene silencing (18).  
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Per definition the two strands of the siRNA are called sense and antisense strand with 
respect to the target mRNA. The antisense strand of the siRNA is also called the guide 
strand because it comprises the sequence complementarity to the mRNA that serves as a 
template for the subsequent mRNA degradation. 
After Dicer processing the siRNA molecules become unwound and the antisense strand 
of the siRNA is assembled into the RNA induced silencing complex (RISC) (19).  
Until now the RISC assembly is not fully understood due to the multitude of different 
proteins that are associated in this complex. So far the only protein that is common to all 
RISC complexes that have been characterized are proteins of the ARGONAUTE (Ago) 
family. The recently solved crystal structure of the ARGONAUTE protein of 
Pyrococcus furiosus suggests that this protein family contributes to the endonuclease 
activity present in activated RISC (16,20-22).  
The antisense bound activated RISC complex called siRISC then recognizes 
complementary mRNA sequences by antisense siRNA mRNA base pairing followed by 
the cleavage of the target mRNA strand (20,21,23). After the cleaved mRNA is released 
from the siRISC the still activated complex can initiate a new cycle of mRNA 
recognition and cleavage thus demonstrating some kind of catalytic turnover.  
The mRNA cleavage site is located between 10 and 11 nt upstream of the 5’ end of the 
siRNA antisense strand. The cleavage event is characterized by the very high sequence 
specificity requiring perfect complementarity between the siRNA antisense strand and 
the mRNA close to the cleavage site (19,24). 
This highly sequence specific and potent gene silencing induced by RNA interference 
demonstrates the potential of this endogenous mechanism for therapeutic applications in 
which disease causing or diseases related genes could be silenced.  
 
1.2 RNA interference for cancer therapy  
Transformation of a normal cell into a neoplastic relentless growing cell is always 
accompanied by the acquisition of multiple mutations that finally induce carcinogenesis. 
Even though mutations occur by statistically driven processes it was possible to identify 
several key genes and the signalling pathways they are involved in that are commonly 
dysregulated in many cancers.  
In this respect RNA interference based gene silencing holds considerable promise for 
the improvement of cancer therapy mainly because of two aspects.  
First of all siRNA based techniques can be used for the high-throughput gene 
expression profiling of cancer cells that rapidly will lead to a wealth of information 
about new promising protein targets that are dysregulated in cancer (reviewed by 
Ameyar-Zazoua et al.) (25). 
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Second of all RNA interference offers the opportunity to silence the expression of any 
cancer associated gene product that might result in anti proliferative or proapoptotic 
effects. In this respect especially proteins that can’t be targeted by conventional small 
molecule drugs are very attractive targets for siRNA based therapy (26).  
In the following section the application of RNA interference for the knock down of 
some of the key cancer associated gene products will be highlighted in order to 
summarize the potential and problems of siRNA based cancer therapy. The examples 
described represent proteins that play important roles in one of the main cancer 
associated pathways:  
 
1. Proteins involved in carcinogenesis:  
Mutations in receptor phosphotyrosine kinases can be found in many human 
malignancies (27,28). Mutated receptor PTKs are oftentimes constitutively active 
and thus represent strong oncoproteins. An example is the BCR-Abl fusion protein 
that is formed after chromosomal rearrangement commonly observed in chronic 
myeloid leukemia. Several groups have designed siRNAs against this fusion protein 
and demonstrated that decreased BCR-Abl protein expression leads to a reduced cell 
growth and a strong induction of apoptosis (29,30).  
 
2. Proteins that mediate the evasion of programmed cell death (apoptosis) 
The ability of a tumour cell population to expand is determined not only by the rate 
of proliferation but also by the rate of cell attrition via programmed cell death 
(apoptosis). Many cancers express anti-apoptotic proteins which make these cells 
resistant to apoptotic stimuli. Therefore, restoration of the sensitivity to apoptosis by 
silencing of anti-apoptotic proteins would have significant therapeutic implications. 
Some of the anti-apoptotic proteins that have been targeted by siRNAs including 
FLIP(31,32), Bcl-2 (31,33,34), Bcl-xL (35), survivin (31) and X chromosome linked 
IAP (XIAP) (31,33,36). It could be shown that the knock down of these proteins 
efficiently re-sensitizes various tumour derived cell lines to apoptotic stimuli by 
chemotherapeutic agents. 
 
3. Proteins involved in tumour host interactions 
The supply of oxygen and nutrients by the vasculature is of fundamental importance 
for cell growth. The maximal possible distance between a cell and a capillary blood 
vessel in a tissue is 100 µm. A fast growing tumour needs to stimulate blood vessel 
growth by the production of angiogenic growth signals. RNA interference mediated 
silencing of these angiogenesis activators thus represents a strategy for cancer 
therapy. Vascular endothelial growth factor (VEGF) is a prominent pro-angiogenic 
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signaling molecule. It was reported by Takei et al. that anti VEGF siRNAs 
significantly reduces the tumour growth in a xenograft tumour mouse model (37).  
Other attributes of malignant tumours include the formation of metastases at sites 
distant from the original tumour. These sub colonies are the cause of approximately 
90% of human cancer death (38). The potential of RNA interference to reduce the 
metastatic potential of tumour cells was demonstrated by the knock down of the 
alpha6beta4 integrin that plays an important role in the invasive phenotype of many 
carcinomas. Reduction of the cell surface expression of this integrin was 
accompanied by a decreased invasiveness of a breast carcinoma cell line in an in 
vitro assay (39).   
 
4. Proteins that mediated the tumour resistance to chemotherapy and/or 
radiotherapy 
A frequently occurring problem in cancer chemotherapy is that tumour cells become 
resistant against a variety of anti-cancer drugs, a trait known as multidrug resistance 
(40). Resistance is mediated by several different mechanisms and proteins. To 
mention here is the inhibition of apoptosis by anti-apoptotic proteins as discussed 
previously and the ATP powered efflux of cytotoxic drugs by ATP dependent 
transporters encoded by MDR genes (41,42). RNA interference mediated silencing 
of MDR1 or MDR3 has been shown to be effective in re-sensitizing cancer cells 
against chemotherapeutic agents (43,44). This approach might be used in 
combination for the therapy of tumours that display MDR mediated resistance.  
 
In conclusion RNA interference can be used for the silencing of a multitude of cancer 
associated genes. Most of the studies presented here demonstrated that siRNA based 
gene silencing efficiently inhibited or reduced tumour cell growth. Therefore siRNA 
based drugs will be especially useful in combination with other therapies that in 
addition lead to the final elimination of neoplastic cells. For future applications it will 
be of special importance to identify target proteins whose silencing directly induces cell 
death without further stimuli. In addition technologies that allow specific in vivo 
delivery are of crucial importance for siRNA based therapies. 
 
1.3 Aptamers  
Aptamers (from Latin aptus: to fit and Greek mere: to bind) are single stranded nucleic 
acid molecules which are able to selectively bind various targets with high affinity. 
Aptamers can be generated in vitro by the SELEX (selective evolution of ligands by 
exponential enrichment) procedure (45,46).  
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This process enables the rapid screening of very large combinatorial oligonucleotide 
libraries by iterative rounds of selection and amplification. The starting library can be 
obtained by combinatorial chemical DNA synthesis techniques. In theory a library 
containing 40 random nucleotides flanked by primer binding regions contains 420 
individual sequences. However, in practice, the complexity of a standard SELEX library 
is limited to about 1014 to 1015 sequences. The principal of the selection process is 
illustrated in (Fig. 1.2). 
 
Fig. 1.2: Scheme of the SELEX process. As the initial step the random DNA or RNA library is incubated 
with the target of choice. Then unbound sequences are removed. Target bound DNA or RNA molecules 
are recovered and amplified via polymerase chain reaction. This process is repeated several times until 
specifically binding sequences can be isolated.  
 
Functional Aptamer sequences are isolated by incubation of the oligonucleotide library 
with the target molecule then unbound sequences are removed and sequences 
comprising target binding affinity are amplified. After several rounds of selection and 
amplification unique aptamer sequences with high affinity and specificity for the target 
can be identified. The high binding specificity of aptamers is mainly provided by so 
called stacking interactions and deep encapsulation of the ligand in nucleic acid 
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structure. In solution aptamers are predominantly unstructured and fold upon 
association with the ligand into complex architectures in which the ligand becomes an 
intrinsic part of the aptamer structure (47). Since the chemical complexity of DNA or 
RNA is limited to the four nucleobases it was possible to develop powerful 
computational secondary structure prediction algorithms (48). Once an aptamer 
sequence is identified it is possible to add further functional nucleotide sequences by 
rational design without affecting the binding affinity. This makes it possible to create 
aptamers with increased avidity (49), bispecific aptamers (49), or even complex 
molecules like allosteric ribozymes that can be switched on and of by ligand binding 
(50). Until now high-affinity Aptamers against many different targets could be 
identified ranging from small molecules, to peptides and proteins or even complex 
supramolecular structures like virus particles (51). Aptamer sequences and target 
information are available in two different comprehensive aptamer databases 
(http://aptamer. icmb.utexas.edu) or (http://mfgn.usm.edu/ebl/riboapt/) (52,53).  
Several aptamers that selectively bind to cell surface proteins or entire cells were 
identified by the SELEX procedure (54-57). These aptamers can be used for imaging 
and diagnostic purposes as well as for the cell type specific delivery of bioactive 
molecules (58,59). In contrast to protein based targeting molecules aptamers tolerate 
harsh conditions applied during chemical conjugation procedures e.g. high temperatures 
or high concentrations of organic solvents. This is why the scope of molecules that can 
be attached to aptamers is broader.  
A very promising aptamer for drug delivery applications is the anti PSMA aptamer 
A10-3. This aptamer was selected against the purified extracellular domain of prostate 
specific membrane antigen (PSMA) and was shown to specifically bind native PSMA 
expressed on the cell surface of prostate carcinoma cells (60). Several studies reported 
aptamer mediated cell surface receptor sepcific delivery of small molecule toxins like 
doxorubicin or doxotaxel or protein toxins like gleonin to PSMA expressing prostate 
tumours (61,62).   
In the present thesis the potential of this aptamer for the delivery of functional siRNAs 
targeting novel apoptosis inducing agents will be evaluated.  
 
1.4 Eucaryotic elongation factor 2  
Eucaryotic elongation factor 2 (EEF2) is a member of to the GTPase superfamily. It 
catalyzes the GTP powered translocation of the aminoacyl tRNA from the A site to the 
P site of the ribosome of the peptide chain elongation step during protein biosynthesis 
(63). The activity of EEF2 is tightly regulated by a specific calmodulin dependent 
protein kinase (64). Downregulation of EEF2 mainly occurs as a result of decreasing 
amounts of nutrients like glucose for instance. EEF2 activity is restored by 
dephosphorylation mediated by protein phosphatase-2A (65). ADP ribosylation of 
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EEF2 by Diphtheria toxin or Pseudomonas A toxin was shown to efficiently inhibit 
protein biosynthesis and subsequently lead to the induction of apoptosis (66,67). These 
toxins have been demonstrated to be effective in various cell types and were used for 
the development of targeted anti cancer agents so called immunotoxins (68). In analogy 
to these protein based toxins RNA interference mediated silencing of EEF2 might be a 
useful strategy for the elimination of cancerous cells. Until now EEF2 was not used for 
the development of cytotoxic siRNAs and thus might represent a new target protein for 
siRNA based cancer therapy.  
 
1.5 Delivery strategies for RNA interference based drug 
According to Lipinski’s Rule of Five a small molecule drug is efficiently taken up by 
mammalian cells if a molecule does not contain more than five hydrogen bond donors, 
does not have more than 10 hydrogen bond acceptors, has a molecular weight below 
500 Da and a log P value less than five. According  to this rule siRNAs are not 
passively taken up by mammalian cells even not by those cells that actively sample their 
environment such as dendritic cells or macrophages (69). In this respect the only 
exceptions are mucosal tissues. In the lung and vagina mucosa for instance siRNA 
uptake is very efficient and occurs even in the absence of transfection reagents (70).  
For most other therapeutic applications of siRNA based drugs however the efficient in 
vivo delivery represents one of the key obstacles. 
In cultured mammalian cells siRNAs can be introduced by the use of cationic 
lipofection reagents. These amphiphilic positively charged polymers interact with the 
siRNA. The resulting positively charged amorphous particles of siRNAs and lipids are 
also called lipoplexes. The fusogenic and membrane destabilizing potential of these 
lipoplexes finally leads to the cellular uptake and release of functional siRNAs (Fig. 
1.3) (71).  
 
Fig. 1.3:  Scheme of siRNA molecules encapsulated in a lipid vesicle,   
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The potential of lipoplexes for the siRNA in vivo delivery has been extensively 
investigated in the last years. Several studies demonstrated that locally injected 
lipoplexes efficiently delivered siRNA to target cells in the eye or to superficial 
tumours. Tolentino et al. and Reich et al. demonstrated  that liposome/siRNA 
complexes either injected intravitreally or subretinally into the eyes of monkeys and rats 
efficiently silenced vascular endothelial growth factor (VEGF) expression and reduced 
ocular neovascularisation (72,73). Based on these results anti-VEGF siRNAs were one 
of the first siRNAs tested in a clinical setting. Another study examining anti tumour 
activity of siRNAs revealed that tumour growth was significantly reduced by the 
intratumoral injection of atelocollagen or liposome encapsulated siRNA targeting 
fibroblast growth factor (74). These results demonstrate that local siRNA delivery is 
well suited for several antitumoral drug delivery applications. Furthermore it has the 
advantage that the effective dose which has to be administered is substantially lower 
compared to systemic siRNA delivery. However this approach is limited to target sites 
that are readily accessible. For the delivery to tissues deep within the body or for 
disseminated targets like lymphocytes of metastatic tumours different strategies have to 
be applied. 
The first successful attempts for the systemic in vivo delivery of siRNAs followed 
hydrodynamic injection protocols previously established for the delivery of DNA into 
cells (75). These protocols are based on the rapid intravenous injection of siRNA 
solutions in large volumes (30 to 40% circulatory blood volume of a mouse). The 
elevated venous pressure after hydrodynamic injection causes a transient reversal of 
blood flow that massively enhances endocytosis. The main organs to target with this 
strategy are liver, kidney, spleen, heart and lung. Most of the studies published so far 
have focused on gene silencing effects in the liver because this organ can be efficiently 
targeted. In an early study McCaffrey and coworkers demonstrated that co-injection of a 
luciferase expression plasmid with siRNA targeting luciferase led to the efficient 
silencing of luciferase expression in the mouse liver (76). Although this study was one 
of the first describing the successful systemic in vivo delivery of functional siRNAs this 
technology is unlikely to be safe enough for human use. Moreover hydrodynamic 
injection seems to be difficult if not impossible to scale up for larger animals.  
Therefore different strategies that potentially are applicable in humans have to be 
developed. One possibility is the covalent conjugation of siRNAs to molecules that 
promote cellular uptake. 
In 2004 Soutcheck et al. conjugated cholesterol to the 3’ end of the antisense strand of a 
chemically modified siRNAs duplex. Cholesterol conjugation mediated the uptake of 
siRNAs via the ubiquitous LDL receptor (77). Furthermore cholesterol conjugation 
increased the serum half live from 6 min for an unconjugated siRNA to 95 min mainly 
because cholesterol is incorporated into circulating lipoprotein particles that are not 
cleared by glomerular filtration in the kidneys. Intravenous injection of cholesterol 
conjugated siRNAs targeting apolipoprotein B (apoB) into mice significantly reduced 
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apoB mRNA in the liver and jejunum. However the major drawback was that very high 
siRNA doses had to be applied (50 mg/kg) (78). 
Conjugation of siRNAs to so called cell penetrating peptides like penetratin or 
transportan was shown to promote cellular uptake but it remains to be seen whether 
these conjugates are effective for siRNA delivery in vivo (79,80). 
Besides the covalent conjugation of siRNAs to molecules that promote cellular uptake 
lipoplex based strategies have also been applied for systemic delivery.  
Intravenous injection of siRNA targeting apoB that were encapsulated in stable nucleic 
acid lipid particles (SNALP) significantly silenced the expression of apoB in the liver of 
both mice and non human primates (81). A single administration of 2.5 mg/kg of 
SNALP siRNA reduces apoB mRNA in the liver by up to 90%. This silencing effect of 
SNALP formulated siRNAs represents a dramatic increase in potency compared to the 
previously described cholesterol conjugated siRNAs. When equally formulated SNALP 
siRNAs targeting the hepatitis B virus (HBV) were intravenously injected into mice that 
carried replicating HBV a significant reduction of HBV DNA could be observed (82). 
However these effects were also restricted to the liver. Since siRNAs which are 
conjugated to lipophilic molecules are cleared from the blood stream mainly in the liver 
this organ might be relatively easy to target. Thus, it remains to be seen whether 
lipoplex or cholesterol conjugation can be used for delivering siRNAs to organs other 
than the liver.  
A general consideration for the therapeutic application of RNA interference is the 
dosage of siRNA based drugs. A disadvantage of non selective systemic delivery 
systems is the large amount of siRNA that has to be administered to achieve efficient in 
vivo gene silencing. For this reason strategies that would allow for the cell type specific 
delivery of siRNAs could be advantageous due to lower dosage requirements. 
The most promising approach is the covalent or non covalent conjugation of siRNAs to 
cell surface targeting molecules. The specific binding affinity of these ligands first leads 
to the accumulation of siRNAs in the target tissue and then promotes siRNA uptake via 
receptor mediated endocytosis (Fig. 1.4).  
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Fig. 1.4: Scheme of cell surface receptor specific delivery of siRNAs. After the binding of the target 
complex the receptor ligand complex is endocytosed. Following the translocation into the cytosol DICER 
processing takes place which produces functional siRNA molecules that are incorporated into the RISC 
complex and mediate gene silencing. 
In an early study siRNAs targeting vascular endothelial growth factor (VEGF) were 
incorporated into polyethylene glycol nanoparticles. These nanoparticles were coated 
with a short tri-peptide (Arg, Gly, Asp, RGD) that specifically binds to integrins 
upregulated at sites of neovasculature. In an in vivo tumour mouse model these particles 
showed tissue specific siRNA delivery as well as specific silencing of VEGF expression 
upon intravenous systemic administration (83). In another approach the RNA binding 
affinity of protamine, a positively charged protein that electrostatically interacts with 
nucleic acids, was exploited for the noncovalent conjugation of siRNAs. A fusion 
protein consisting of a heavy-chain antibody fragment (Fab) specifically binding to 
HIV-1 envelope glycoprotein 160 (gp-160) was fused to protamine. These Fab-siRNA 
targeting complexes were specifically taken up by gp-160 expressing cells and specific 
siRNA mediated gene silencing was induced. In a tumour mouse model outgrowth of 
gp-160 positive tumours was slowed down after systemic intravenous administration of 
protamine Fab complexed siRNAs targeting three different oncogenes. Additionally, 
cell type specific delivery to a breast cancer cell line was achieved by an ERBB2 
specific single chain protamine fusion protein (84). In a follow up study it was shown 
that this strategy was also successful for the specific delivery of siRNAs to activated 
leucocytes in vivo (85). 
As previously described RNA aptamers are well suited for drug delivery applications. 
They are especially well suited for the delivery of siRNAs since this strategy only 
involves RNA which in general is not immunogenic. Therefore repeated administration 
of aptamer siRNA targeting complexes should be well tolerated. McNamara et al. 
created fully RNA based aptamer-siRNA chimeras. The siRNA portion was fused to the 
3’ end of an aptamer specifically binding prostate specific membrane antigen (PSMA). 
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A protein predominantly expressed on the cell surface of prostate carcinoma cells. 
These chimeras were specifically taken up via receptor mediated endocytosis and 
induced siRNA mediated gene silencing of polo like kinase 1 (plk1). After repeated 
administration of these chimeras knock down of pkl1 led to cell death. In a prostate 
carcinoma mouse model tumour growth could be reduced after repeated intratumoural 
injection of aptamer siRNA chimeras (86). Two other groups also demonstrated 
aptamer mediated siRNA delivery with non-covalent aptamer siRNA conjugates. Chu et 
al. created targeting complexes by using streptavidin as bridging carrier protein. After 
biotinylated siRNAs and biotinylated aptamers were loaded onto streptavidin, cell 
surface receptor specific uptake and siRNA mediated gene silencing effects were 
demonstrated (87). Besides that Guo et al. exploited the affinity of interlocking right- 
and left-hand loops of packaging RNA (pRNA) dimers. A CD-4 specific aptamer was 
incorporated into one monomer and siRNAs targeting survivin into the other monomer 
of this pRNA. Finally both monomers were assembled via loop-loop interactions. Here 
as well cell surface receptor specific siRNA delivery was shown (88).  
1.6 Prostate specific membrane antigen (PSMA) 
In 1987 Horoszewicz et al. derived a monoclonal antibody (7E11-C5) from 
immunization of partially purified membrane preparations of the lymph node prostatic 
adenocarcioma cell line (LNCaP) that were isolated from a human prostate carcinoma. 
Later on the antigen of this antibody was determined to be prostate specific membrane 
antigen (89). A 2.65 kb cDNA fragment encoding the PSMA gene was cloned and 
mapped to chromosome 11p11.2.  Transfection of the full length cDNA encoding 
PSMA into PSMA negative PC-3 cells led to positive cell surface staining using the 
7E11 antibody (90,91). PSMA was found to be expressed in every prostatic tissue. The 
expression level of PSMA significantly increases proportional to tumour aggressiveness 
(92,93). Furthermore PSMA expression is closely associated with androgen-
independent prostate cancer (PCa) and the expression level is elevated both in primary 
and metastatic tumour specimen (93). Some reports have also indicated limited PSMA 
expression in extraprostatic tissues. However the expression levels were at least two 
orders of magnitude reduced compared to those observed in the prostate (94).  
The extracellular domain of PSMA is highly glycosylated and shares modest sequence 
homology to the transferrin receptor (TfR). The biological function of PSMA is still 
unknown. It is noteworthy that it forms homodimers and is constitutively internalized 
from the cell surface of PSMA expressing LNCaP cells. Binding of antibodies to PSMA 
increases the rate of internalization indicating that these antibodies might act like a still 
unknown ligand (95,96).  
The highly restricted expression of PSMA and its upregulation in advanced carcinomas 
and in metastatic prostate cancer show the very high potential of PSMA to serve as 
biomarker for both diagnosis and therapy.  
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1.7 The lymphocyte activation marker CD30 
This antigen was discovered to be expressed on cultured Hodgkin/Reed–Sternberg (H-
RS) cells using a monoclonal antibody mAb (Ki-1) (97,98). It belongs to the tumour 
necrosis factor receptor (TNF-R) superfamily. The extracellular domain of this integral 
transmembrane protein consists of six cysteine rich pseudorepeats that are characteristic 
for TNF-receptors. The cytoplasmic domain consists of 188 amino acids and in contrast 
to the extracellular portion diverges significantly from all other TNF-R family members 
(99). The naturally occurring CD30 ligand (CD30L) has also been identified and cloned 
(100). Until now the biological function and signaling pathways of CD30 and CD30L 
are not fully understood. Emerging information indicates that activation of CD30 
provides pleiotropic signals. On the one hand CD30L mediates activation of CD30 
enhanced cell proliferation of a “T-cell-like" Hodgkin's disease-derived cell line in vitro 
and on the other hand CD30L induces cytolytic cell death in large-cell anaplastic 
lymphoma cell lines (101,102).  
CD30 expression is restricted to cells of the immune system and highly dependent on 
activation and proliferation. For instance its expression in resting PB cells can be 
induced by the activation with mitogens or viruses (103). Overexpression of CD30 has 
been documented in lymphoproliferative disorders and became a crucial parameter for 
the characterization of Hodgkin Disease (HD), non-Hodgkin lymphoma (NHL) and 
anaplastic large cell lymphoma (ALCL) (104). Since the extracellular domain of CD30 
is proteolytically cleaved of the cell surface the soluble receptor (sCD30) represents a 
promising serum tumour marker (105,106). In conclusion CD30 represents one of the 
most promising target antigens for the immunotherapy of malignant lymphomas such as 
Hodgkin lymphoma or anaplastic large-cell lymphoma. Until now several studies 
demonstrated the selective and potent anti tumour activity of chemically- or genetically-
linked antibodies or antibody-fragments targeting the CD30 receptor in vitro as well as 
in mouse models (107,108).  
 
1.8 Aim of the thesis 
An important feature for siRNA-based drugs is the potential to abolish the expression of 
any disease-causing or disease related protein by highly specific and efficient 
degradation of a target mRNA (109,110).  
In case of malignant diseases the most promising approach of RNA interference based 
therapy is the elimination of neoplastic cells by the siRNA mediated silencing of genes 
that are crucial for cell viability. Up to now most studies that aimed for the RNA 
interference mediated elimination of cancer cells have targeted antiapoptotic or 
oncogenic proteins.  
In the present work it was aimed to identify a novel protein whose siRNA mediated 
knock down would efficiently induce cell death in various cancer derived cell lines. In 
 
20 Introduction 
this respect targeting key components of the translational machinery represents a new 
approach for the identification of cytotoxic siRNAs.  
A promising candidate target gene for RNAi is eukaryotic elongation factor 2 (EEF2) 
since it is known that inhibition of EEF2 by various bacterial or plant derived protein 
based toxins efficiently induces cell death.  
The efficiency of siRNAs targeting EEF2 efficiency will be evaluated by quantitative 
real time RT-PCR (qPCR) and western blot analysis. Finally the cytotoxic potency of 
these siRNAs will be monitored by using colorimetric cell viability assays. 
Besides the identification of novel target genes for RNA interference the development 
of techniques and strategies that allow for the cell-type specific delivery of siRNAs and 
are suitable for systemic administration regimens are of crucial importance  
In this respect it could be demonstrated by Inga Neef (Fraunhofer IME, Aachen) that 
antigen specific delivery of functional siRNAs was possible by fusing a shRNA to a cell 
surface receptor specific aptamer. However the observed effects were only moderate. 
The aim of this part of the thesis will be to develop strategies that will enhance the 
biological activity of aptamer siRNA transcripts. The working hypothesis here is that 
transcripts with a higher avidity will be taken up more efficiently and thus display 
higher efficacy. The aptamer building block used in this study will be the anti PSMA 
aptamer xPSM-A10-3 (60).  
The design of bivalent aptamer siRNA transcripts will be performed according to 
secondary structure prediction analysis. Subsequently the affinity will be determined via 
flow cytometry. Quantitative internalization assays will reveal potential differences in 
the internalization porperties. Finally the overall gene silencing activity of bivalent 
aptamer siRNA transcripts will be compared to their monovalent counterpart.  
The third part of this thesis will examine the generation of covalent antibody-siRNA 
conjugates for the cell type specific delivery of functional siRNAs. Until now no report 
about the functionality of covalent antibody siRNA conjugates has been published in 
the literature. Therefore it will be anticipated to establish conjugation strategies that 
mediate efficient conjugation and retain antibody binding activity. Two different 
hereterobifunctional linker formats will be evaluated. Finally cell type specific gene 
silencing will be investigated. 
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Fig. 1.5:  Flow chart of the Ph.D. thesis 
 
  
2 Materials and Methods 
 
2.1 Materials 
2.1.1 Chemicals 
Unless otherwise noted consumables and chemicals were purchased from Acros 
Organics (Bruessel), Becton Dickinson Bioscience (Franklin Lakes, USA), Bio chrom 
(Berlin), BioRad (München), Biozym (Oldendorf), Clontech (Heidelberg), Corning Inc. 
(Schiphol-Rijk, Nederland), Cytogen (Obermörlen), Dharmacon (Lafayette, USA), 
Eppendorf (Hamburg), ICN (Eschwege), Greiner (Solingen), Hampton Research (Aliso 
Viejo), Hewlett-Packard (München), Invitrogen (Eggenstein),  Codak (Stuttgart), KMF 
Laborchemie (St. Augustin), Millipore (Eschborn), MWG-Biotech (Ebersberg), New 
England Biolabs (NEB; Schwalbach), Nunc (Wiesbaden), Novagen (Madison, USA), 
Pall Filtron (Northborough, USA), Perkin-Elmer (Applied Biosystems, Foster City, 
USA), Pierce (Rockford), Promega (Mannheim), Qiagen (Hilden), Roche Molecular 
Biochemicals (Mannheim), Roth (Karlsruhe), Sarstedt (Nümbrecht), Schott-Glaswerke 
GmbH (Neufahrn/San Diego), Serva (Heidelberg), Sigma (Deisenhofen), Starlab 
(Ahrensburg), Whatman (Maidstone, England), VWR (Darmstadt). 
 
2.1.2 Media stock solutions and buffers  
Standard medium buffer and stock solutions were prepared according to standard 
procedures using de-ionized water. Solutions were sterilized by autoclaving (25 min/ 
121 °C/ 2 bar). Heat-sensitive components, such as antibiotics, were prepared as stock 
solutions, filter-sterilized (0.2 μm) and added to the medium/buffer after cooling below 
50 °C. 
All buffers and solutions intended to be used for RNA work were prepared in DEPC 
treated water (H2O-DEPC). H2O-DEPC was prepared by adding 1,5 mL DEPC/L the 
solution was vigorously stirred over night and subsequently autoclaved.  
 
2.1.3 Standard buffer and media compositions 
The folowing standard buffers and media were used: 
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Tab. 2.1:  Standard Media and Buffer compositions 
No. Buffer Composition Concentration 
1 10x PBS (pH 7.4) NaCl  
KCl  
Na2HPO4 x 12H2O  
KH2PO4  
1.37 
27  
81 
15 
 M 
 mM 
 mM       
 mM 
2 1x PBST 
 
1x PBS (pH 7.4) 
Tween 20  
 
0.05 
 
% (w/v) 
3 50x TAE 
Electrophoresis 
Buffer (pH 7.5) 
Tris-base  
Glacial acetic acid  
EDTA  
2      
5.7 
50  
M 
% (v/v) 
mM 
4 5x OrangeG 
Loading Buffer 
OrangeG  
Glycerol  
 
0,01 
30    
in 1x 
TAE 
% (w/v) 
% (v/v) 
 
5 5x SDS PAGE 
running buffer  
 
Tris-HCl (pH 8.3)  
Glycine  
SDS  
125  
960 
0.5 
mM 
mM 
% (w/v) 
6 Coomassie 
Staining Solution 
Coomassie bb. G-250  
Methanol   
Glacial acetic acid  
0.25 
50    
9      
%(w/v) 
% (v/v) 
% (v/v) 
7 Coomassie 
Destaining 
Solution 
Methanol  
Glacial acetic acid  
10    
10 
% (v/v) 
% (v/v) 
8 5x Reducing 
Protein Loading 
Buffer 
Tris-HCl (pH 6.8)  
Glycerol  
SDS  
Bromphenolblue  
ß-Mercaptoethanol  
62.5 
30  
4    
0.05  
10  
mM 
% (v/v) 
% (w/v) 
% (w/v)  
% (v/v) 
9 5x Non-Reducing 
Protein Loading 
Buffer 
Tris-HCl (pH 6.8)  
Glycerol  
SDS  
Bromphenolblue  
62.5 
30 
4    
0.05  
mM 
% (v/v) 
% (w/v)  
% (w/v) 
10 10x TBE 
electrophoresis 
running buffer 
Tris-HCl 
H3BO3 
EDTA (0,5 M) 
0,685  
0,9      
0,02  
M 
M 
M 
11 2x denaturing 
RNA loading 
buffer 
Formamide 
EDTA 
SDS 
Bromophenol Blue. 
95     
18     
0.025 
0,01 
% (v/v) 
mM 
% (w/v) 
% (w/v) 
12 8% denaturing 
Urea PAGE gel 
(30 mL) 
Acrylamide/Bisacrylamide(30/1) 
Urea 
TEMED 
APS, (20%, w/v) 
H2O 
x 
7 
30 
200 
 
mL (8%) 
M 
µL 
µL  
add 
30mL 
13 native PAGE gel Acrylamide/Bisacrylamide (30/1) 
TAE buffer 
x 
 
µL 
1x 
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14 SDS PAGE gel  
(Separating gel) 
 
Acrylamide/Bisacrylamide 
(30/1) 
Tris-HCl (pH: 8,8) 
SDS (10 %, w/v) 
TEMED 
APS (20%, w/v) 
x  
375 
0,1    
0,1 
0,1  
mL 
mM 
% (w/v) 
% (v/v)  
% (v/v) 
15 SDS PAGE gel 
(stacking gel) 
Acrylamid/Bisacrylamide (30/1) 
Tris-HCl (pH : 6,8) 
SDS  
TEMED 
APS 
5 
150 
0,1  
0,1 
0,1  
% (w/v) 
mM 
% (m/v) 
% (v/v) 
% (v/v) 
16 LB (pH: 7) NaCl 
Peptone 
Yeast extract 
1 
1 
0,5 
% (w/v) 
% (w/v) 
% (w/v) 
 
 
2.1.4 Buffers for RNA work 
 
Tab. 2.2:  Buffers used for RNA work 
No. Buffer Composition Concentration 
1 RNA PAGE elution 
buffer NaOAc pH: 5,4 0,3 M 
2 2x RNA denaturing 
PAGE loading buffer 
Formamide 
EDTA 
SDS 
95 
18 
0,025 
% (v/v) 
% (w/v) 
% (w/v) 
3 1x siRNA deprotection 
buffer pH: 3,8 with 
TEMED 
NaOAc 
TEMED 
100 
x 
mM 
µL 
4 5 x siRNA resuspension 
buffer pH: 7,4 – 7,6 
(with KOH) 
HEPES 
KCl, 
MgCl2 
30 
1 
1 
mM 
mM 
mM 
5 1 x RNA binding buffer, 
pH: 7,4 
HEPES 
MgCl2 
CaCl2 
20 
1 
1 
mM 
mM 
mM 
6 1x RNA internalization 
buffer 
pH: 7,4 
HEPES 
MgCl2 
CaCl2 
Glucose 
20 
1 
1 
16 
mM 
mM 
mM 
mM 
7 1 x siRNA conjugation 
buffer-1, 
pH: 7,4 
Na2HPO4 
NaCl 
100 
150 
mM 
mM 
8 1 x siRNA conjugation 
buffer-2, 
pH: 8 
Na2HPO4 
NaCl 
100 
150 
mM 
mM 
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2.1.5 Antibodies 
The following antibodies were used: 
Tab. 2.3:  Antibodies used 
Antibody Target Characteristic 
mouse monoclonal, Ki-4 
(University Hospital Cologne) CD30 receptor monoclonal 
mouse-anti-penta-his 
[α-penta His Ab] 
(Qiagen) 
C-terminal his-tag monoclonal 
goat-anti-mouse 
[GαMHRPO (α-IgG Fc)] 
(Sigma) 
Fc of mouse IgG 
polyclonal,  conjugated to 
horseradish peroxidase 
(HRPO) 
goat-anti-rabbit 
[GαRAP] 
(Dianova) 
Fc of rabbit IgG polyclonal, conjugated to alkaline phosphatase 
goat-anti-rabbit 
[GαRHRPO] 
(Dianova) 
Fc of rabbit IgG 
polyclonal, conjugated to 
horseradish peroxidase 
(HRPO) 
rabbit-anti-eEF2 (Cell 
Signaling Technologies) 
eucaryotic elongation 
factor 2 (eEF2) polyclonal 
mouse-anti-PSMA-3C6 
(Northwest Biotherapeutics)  
prostate specific 
membrane antigen 
(PSMA) 
monoclonal 
mouse-Tag100 (Qiagen) MAPK1 (human/mouse) monoclonal 
mouse-anti-54k (Fraunhofer 
IME) 54k protein monoclonal 
goat-anti-mouse-FITC 
[GαΜFITC (α-IgG Fc)] Fc of mouse IgG 
monoclonal, conjugated to 
FITC 
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2.1.6 Reaction kits and Enzymes 
Unless otherwise noted enzymes were purchased from NEB, Roche Molecular 
Biochemicals, MWG-Biotech, Invitrogen, Biozym or Promega. The following kits were 
used according to manufacturers recommendations.  
 
Tab. 2.4:  Standard reagents and kits used 
Purpose Reagent / Kit Company 
DNA extraction form 
Agarose gels 
QIAquick Gelextraction Kit 
QiaExII Agarose Gel Extraction Kit 
Qiagen 
PCR product purification QIAquick „PCR-Purification“ Kit Qiagen 
total RNA isolation NucleoSpin® RNA II Macherey-
Nagel 
PCR product cloning TOPO TA cloning kit with pCR 
2.1TOPO Vector 
Invitrogen 
DICER cleavage In vitro DICER assay kit Peqlab 
RNA transcription Durascribe T7 transcription kit Biozym 
Cell viability  Cell Proliferation Kit II (XTT)  Roche Applied 
Sciences 
DNA plasmid isolation 
(mini scale) 
QIAprep Spin Miniprep Kit Qiagen 
DNA plasmid isolation 
(maxi scale) 
Pure Yield Plasmid Maxiprep System Promega 
Interferon β detection Human IFN Beta ELISA Kit PBL Interferon 
Source, USA 
Apoptosis assay Apo-ONE Caspase-3/7 assay  Promega 
 
 
 
2.1.7  Synthetic oligonucleotides  
Synthetic oligonucleotides were provided by MWG-Biotech. Standard synthesis 
conditions were applied for oligonucleotides up to 50 nt. Oligonucleotides exceeding a 
length of 50 nucleotides were further HPLC purified (HPSF). 
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Tab. 2.5:  Names and sequences of Synthetic oligonucleotides 
No. Name Sequence 
1 PSMA Apt trunc GGGAGGACGATGCGGATCAGCCATGTTTACGTCACTCCTTGTCAATCCTCATCGGC 
2 5’PSMA TAATACGACTCACTATAGGGAGGACGATGCG 
3 3’ PSMA GCCGATGAGGATTGAC 
4 3’PSMA-GFP CGGCAAGCTGACCCTG 
5 PSMA-1GFP GGGAGGACGATGCGGATCAGCCATGTTTACGTCACTCq 
6 PSMA-2GFP GCTTGCGCCGATGAGGATTGACAAGGAGTGACGTAAACATGGCTG 
7 PSMA-3GFP CCTCATCGGCGCAAGCTGACCCTGAAGTTCATGAAGCTTGGAACTTC 
8 PSMA-4GFP CGGCAAGCTGACCCTGAAGTTCCAAGCTTCATGAACTTC 
9 PS-EEF2-2 GCGCTGCCGATGAGGATTGACAAGGAGTGACGTAAACATGGCTGA 
10 PS-EEF2-3 ATCCTCATCGGCAGCGCCATCATGGACAAGAATTGAAGCTTCTTCTTG 
11 PS-EEF2-4 CCGCGCCATCATGGACAAGAAGAAGCTTCAATTCTTGTCCAT 
12 PS-EEF2-3’P CCGCGCCATCATGGAC 
13 3’ biv ann - 1 TTAATTCTTGTCCATGATGG  
14 PSMA biv-1+T7 TAATACGACTCACTATAGGGAGGACGATGCGGATCAGCCATGTTTACGTCACTCC 
15 PSMA biv-1-1 GGGAGGACGATGCGGATCAGCCATGTTTACGTCACTCC 
16 PSMA biv-1-2 CGCAATTTTTAGCCGATGAGGATTGACAAGGAGTGACGTAAACATGGC 
17 PSMA biv-1-3 CCTCATCGGCTAAAAATTGCGCCATCATGGACAAGAATTAATTAAGGGAGG 
18 PSMA biv-1-4 CGTAAACATGGCTGATCCGCATCGTCCTCCCTTAATTAATTCTTGTCCATG 
19 PSMA biv-1-5 GCGGATCAGCCATGTTTACGTCACTCCTTGTCAATCCTCATCGGCAAAAA 
20 PSMA biv-1-6 CCGCGCCATCATGGACAAGAATTTTTGCCGATGAGGATTGACAA 
21 PSMA biv-2-1 GGGAGGACGATGCGGATCAGCCATGTTTACGTCACTCCTTGTCAATCCTC 
22 PSMA biv-2-2 AATTGACGGGCAGATAGGCCTAATTTTAGCCGATGAGGATTGACAAGGAGTGACGTAAA 
23 PSMA biv-2-3 GGCCTATCTGCCCGTCAATTAAAAATTGGGAGGACGATGCGGATCAGCCATGTTTACG 
24 PSMA biv 2-4 GATGGCGCTGCCGATGAGGATTGACAAGGAGTGACGTAAACATGGCTGATCCGCA 
25 PSMA biv 2-5 CATCGGCAGCGCCATCATGGACAAGAATTGAAGCTTCTTCTTGTCCATGATGGCGC 
26 PSMA biv 2-6 AAAGGCCTATCTGCCCGTCAATTTTTTTCCGCGCCATCATGGACAAGAAGA 
27 EEF2 forw. ATGGTGAACTTCACGGTAGAC 
28 EEF2 rev. GACTTGATGGTGATGCAACGGACTTGATGGTGATGCAACG 
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2.1.8 Synthetic siRNA sequences and targets  
Synthetic siRNA oligonucleotides were synthesised by Qiagen (Hilden) or by 
Dharmacon (Lafayette, USA). Prior to use single stranded siRNA oligonucleotides were 
deprotected and annealed according to manufactures recommendations. The following 
sequences were used: 
 
Name:   siEEF2 sequence 1 (Qiagen) 
Target: eukaryotic elongation factor 2 (eEF2) 
Acession number NC_000019.8 
Target DNA sequence: CAAGGCCTATCTGCCCGTCAA 
RNA sense: r(AGG CCUAUCUGCCCGUCAA)dTdT 
RNA antisense: r(UUGACGGGCAGAUAGGCCU)dTdG 
  
Name:   siEEF2 sequence 1 (Qiagen) 
Target: eukaryotic elongation factor 2 (eEF2) 
Acession number NC_000019.8 
Target DNA sequence: CCGCGCCATCATGGACAAGAA 
RNA sense: r(GCGCCAUCAUGGACAAGAA)dTdT 
RNA antisense: r(UUCUUGUCCAUGAUGGCGC)dGdG 
  
Name:   siEEF2 sen / siEEF2 as (Dharmacon) 
Target: eukaryotic elongation factor 2 (eEF2) 
Acession number NC_000019.8 
Target DNA sequence: CCGCGCCATCATGGACAAGAA 
RNA sense: G*C*GCCAUCAUGGACAAGAA*mU*mUT-N3-NH2 
RNA antisense: U*U*C UUG UCC AUG AUG GCG C*mG*mG 
 N*N =  phosphothioate phosphodiester backbone bond  mN   = 2’-O-methyl modified nucleotide 
  
Name siGFP  
Target: enhanced green fluorescent protein (eGFP) 
Acession number --- 
Target DNA sequence: CGGCAAGCTGACCCTGAAGTTC  
RNA sense: GAACUUCAGGGUCAGCUUGCCG 
RNA antisense: GAACUUCAGGGUCAGCUUGCCG 
  
Name:   siGFP sen/ siGFP as (Dharmacon) 
Target: enhanced green fluorescent protein (eGFP) 
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Acession number -- 
Target DNA sequence: CGGCAAGCTGACCCTGAAGTTC 
RNA sense: G*A*ACUUCAGGGUCAGCUUGC*mC*mG-N3-NH2 
RNA antisense: G*A*ACUUCAGGGUCAGCUUGC*mC*mG 
 N*N =  phosphothioate phosphodiester backbone bond  mN   = 2’-O-methyl modified nucleotide 
  
Name:   negative control siRNA (Qiagen) 
Target: no target (nonsilencing) 
Acession number no homolog DNA in human genome  
Target DNA sequence: --- 
RNA sense: UUCUCCGAACGUGUCACGUdTdT  
RNA antisense: ACGUGACACGUUCGGAGAAdTdT  
  
Name:   negative control siRNA  FITC (Qiagen) 
Target: no target (nonsilencing) 
Acession number no homolog DNA in human genome 
Target DNA sequence: --- 
RNA sense: sequence not provided by the  
RNA antisense: manufacturer 
  
Name:   siMAPK1 
Target: mitogen-activated protein kinase 1 (MAPK1) 
Acession number NC_000022.9 
Target DNA sequence: AATGCTGACTCCAAAGCTCTG 
RNA sense: UGCUGACUCCAAAGCUCUGdTd 
RNA antisense: CAGAGCUUUGGAGUCAGCAdTdT 
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2.1.9 RNA-Aptamer sequences 
All RNA aptamers were synthesised by in vitro transcription (2.2.4.8). As template 
either PCR products (2.2.4.4) or linearized plasmid DNA was used (2.2.4.2). Sequences 
of the final transcripts are provided in Tab. 2.6.: 
 
Tab. 2.6: Sequences of RNA Aptamers used  
Aptamer Sequence 
xPSM-A10-
3 
GGGAGGACGAUGCGGAUCAGCCAUGUUUACGUCACUCCUUGUCAAUCCUCAUCGG
C 
xPSM-A3-
siGFP 
GGGAGGACGAUGCGGAUCAGCCAUGUUUACGUCACUCCUUGUCAAUCCUCAUCGG
CGCAAGCUGACCCUGAAGUUCAUGAAGCUUGGAACUUCAGGGUCAGCUUGCCG 
xPSM-A3-
siEEF2 
GGGAGGACGATGCGGATCAGCCATGTTTACGTCACTCCTTGTCAATCCTCATCGG
CAGCGCCATCATGGACAAGAATTGAAGCTTCTTCTTGTCCATGATGGCGCGG 
xPSM-A3-
biv an I 
GGGAGGACGATGCGGATCAGCCATGTTTACGTCACTCCTTGTCAATCCTCATCGG
CAGCGCCATCATGGACAAGAATTAA 
xPSM-A3-
biv an II 
GGGAGGACGATGCGGATCAGCCATGTTTACGTCACTCCTTGTCAATCCTCATCGG
CATTCTTGTCCATGATGGCGCGG 
xPSM-B1-
siEEF2 
GGGAGGACGAUGCGGAUCAGCCAUGUUUACGUCACUCCUUGUCAAUCCUCAUCGG
CUAAAAAUUGCGCCAUCAUGGACAAGAAUUAAUUAAGGGAGGACGAUGCGGAUCA
GCCAUGUUUACGUCACUCCUUGUCAAUCCUCAUCGGCAAAAAUUCUUGUCCAUGA
UGGCGCGGGAGCUCG 
xPSM-B2-
siEEF2 
GGGAGGACGAUGCGGAUCAGCCAUGUUUACGUCACUCCUUGUCAAUCCUCAUCGG
CUAAAAUUAGGCCUAUCUGCCCGUCAAUUAAAAAUUGGGAGGACGAUGCGGAUCA
GCCAUGUUUACGUCACUCCUUGUCAAUCCUCAUCGGCAGCGCCAUCAUGGACAAG
AAUUGAAGCUUCUUCUUGUCCAUGAUGGCGCGGAAAAAAAUUGACGGGCAGAUAG
GCCUUUGAGCUCG 
xPSM-B2-
non 
GGGAGGACGAUGCGGAUCAGCCAUGUUUACGUCACUCCUUGUCAAUCCUCAUCGG
CUAAAAUUUUCUCCGAACGUGUCACGUUUAAAAAUUGGGAGGACGAUGCGGAUCA
GCCAUGUUUACGUCACUCCUUGUCAAUCCUCAUCGGCAGCAAGCUGACCCUGAAG
UUCAUGAAGCUUGGAACUUCAGGGUCAGCUUGCUUAAAAAAAACGUGACACGUUC
GGAGAAUUGAGCUCG 
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2.1.10   Bacterial strains and Vector Systems 
Tab. 2.7 shows the bacterial strains that were used for the production and cloning of  
plasmid DNAs. 
Tab. 2.7:  Bacterial strains used 
Bacterial strain Genotype 
XL1-blue RecA1 endA1 gyrA96 thi-1 hsdR17supE44 relA1 lac 
[F’proAB lacIq ZΔM15 Tn10 (Tetr)] (Stratagene, La Jolla, 
USA) 
DH5 α F- φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 
hsdR17(rk-, mk+) phoA supE44thi-1 gyrA96 relA1 tonA 
(confers resistance to phage T1) 
 
 
Different vectors were used for cloning purposes and for the production of RNA 
aptamer constructs via run off in vitro transcription 
Tab. 2.8:  Vecor systems used 
Vector Purpose 
CR®2.1-TOPO® DNA fragment cloning  
pUC-19 Template for runoff transcription 
pGA6 Template for runoff transcription 
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2.1.11 Equipment and applications  
 
Tab. 2.9: Equipment used   
Application Equipment 
Centrifuges Beckman, Eppendorf 
Gelelectrophoresis Mini Protean III gel chamber (BioRad), XCell II Blot 
Module (Invitrogen), Protein Gel-Apparatus and supplies 
Mini PROTEAN II™, Gel Air Dryer (BioRad) 
DNA sequencing ABI Prism 3700 Capillary-Sequencer (Perkin- 
Elmer) 
Incubators Innova™ 4340 incubator shaker (NewBrunswick Scientific), 
Thermomixer compact (Eppendorf) 
Vortex Vortex-Genie 2 (Scientific Industries Inc., Bohemia, USA) 
PCR-Cylers Primus 96 Plus (MWG-Biotech), Programmable Thermal 
Controller PTC-200™ (MJ Research Inc., Watertown, USA) 
Real time PCR Roche Lightcycler 1.0 system; Roche 
Incubators Innova™ 4340 incubator shaker (NewBrunswick Scientific), 
Incubator (Heraeus Instruments), Thermomixer compact 
(Eppendorf) 
Laminar flow Hera Safe HS12 (Kendro). 
Photometer Biophotometer (Eppendorf) 
ELISA plate 
reader 
Elisareader ELx808 (Bio-TEK) 
 
Transiluminator Molecular Imager Gel Doc XR System; Biorad 
Software AIDA image analyzer 
Electroblotting 
equipment 
Mini Trans-Blot Cell (Biorad) 
Flow cytometry FACS Excalibur, Becton Dickinson 
Pipetting Pipetman P (Gilson) Multichannel Pipettes (Eppendorf) 
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2.2 Methods 
2.2.1 Cell culture 
The hodgkin lymphoma cell line L540cy (university hospital cologne), the human 
prostate carcinoma cell line LNCaP (ATCC CRL-1740) and PC-3 (ATCC CRL-1435) 
and the human mammary adenocarcinoma cell line MCF-7 (ATCC HTB-22) were 
cultured in RPMI 1640 medium (Gibco, Karlsruhe, Germany) supplemented with 10% 
heat-inactivated fetal bovine serum (FBS) (Gibco), 50 µg/ml penicillin and 50 µg/ml 
streptomycin. The cells were maintained in vitro at 37°C in a humidified atmosphere of 
5% CO2 
2.2.2 Electrophoresis protocols 
2.2.2.1 Agarose gel electrophoresis 
DNA fragments (2.2.4.4) were electrophoretically (U: 100V run time 20 to 60 min) 
separated on 1,5 to 2,5% (w/v) agarose gels containing 0,1 µg/mL ethidium bromide 
prepared in TAE buffer (2.1.3). As molecular weight standard the 2log DNA ladder 
(NEB) was used. DNA was visualized on a transilluminator (Geldoc XR; Biorad). For 
preparative agarose gels the same protocol was applied. After the run was completed the 
DNA band of interest was excised and the DNA recovered by the Qiagen gel extraction 
kit (2.1.6). 
 
2.2.2.2 Analytical SDS PAGE gel electrophoresis 
Discontinuous SDS PAGE electrophoresis was performed for the separation of proteins. 
8 to 15% (w/v) SDS gels were used. Proteins were visualized by staining with 0,25 % 
(w/v) Coomassie brilliant blue G250 (2.1.3). Gels were run under non-reducing 
conditions in order to maintain native disulfide bonds.  
 
2.2.2.3 Urea PAGE gel electrophoresis 
RNA fragments were separated using urea PAGE gel electrophoresis. The RNA sample 
was mixed with an equal volume of denaturing RNA loading buffer (2.1.4 No. 2) and 
heated to 95°C for 3 min. Then the hot RNA solution was immediately loaded onto the 
gel and electrophorized at 250 V (for preparative gels) or at 160 V (for analytical gels) 
for 30 min to 1.5 h. As molecular weight standard the RNA ribomax ladder (Ambion) 
was used. For preparative gels the RNA was visualized by UV shadowing. For 
analytical gels the gel was subsequently stained in 0,1 µg/mL ethidium bromide staining 
solution for 5 min. RNA bands were then visualized on a transilluminator.  
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2.2.2.4 Analytical native PAGE gel electrophoresis 
siRNAs and antibody-siRNA conjugates were analyzed by native PAGE 
electrophoresis. For siRNA separation a 15% gel was used (15% w/v acrylamide in 
TAE buffer) and for antibody-siRNA conjugates a 5% gel (15% w/v acrylamide in TAE 
buffer) was used. Samples were loaded in 1x non-denaturing orange G DNA loading 
dye (2.1.3 No.4). RNAs were visualized after ethidium bromide staining on a 
transilluminator. Proteins were subsequently visualized by staining with Coomassie 
brilliant blue G250. 
2.2.3 Methods for the evaluation of siRNA mediated gene silencing 
2.2.3.1 siRNA transfection 
All transfections were performed using RNAifect (Qiagen) following the 
manufacturer’s recommendations. Briefly, 1-3 x 104 cells/well were seeded in 96-well 
plates and grown overnight. RNAifect (1.5 µl) was mixed with 50 µl RPMI medium 
containing the appropriate concentration of siRNA (2.1.8) and incubated for 10 min at 
room temperature before transferring to the cells (final volume 100 µl). The cells were 
harvested after 12 h incubation for gene silencing analysis. Cell viability was assayed 
after 48 h.  
 
2.2.3.2 Analysis of transfection efficiencies by fluorescence microscopy 
Transfection efficiencies of various cell lines were determined by Fluorescence 
mikroskopy. Transfection was performed as described in (2.2.3.1). 200 nM of FITC 
labelled control siRNA (2.1.8) was used for transfection. 12 h post transfection the 
medium was exchanged and cells were washed twice with 1xPBS in order to remove 
free siRNA from the wells. Then cells were analyzed under a fluorescence mikroskope 
at a magnification of. Transfection efficiencies were calculated by determining the ratio 
of visibly stained cells to unstained cells.  
 
2.2.3.3 Total RNA preparation 
Total cellular RNA was isolated from as few as 1x104 cells using the Macherey Nagel 
NucleoSpin® RNA II kit according to manufactures recommendation. The final elution 
step was performed with 30 µL H2O in order to achieve higher RNA concentration. 
 
2.2.3.4 First strand cDNA synthesis  
cDNA first strand synthesis was performed by using total cellular RNA extracts 
(2.2.3.3). From a standard extraction approximately 10 µL were used as template RNA 
for cDNA synthesis which was performed by using random Hexamer primers and 
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Superscript III RNA polymerase (Invitrogen) following the manufacturer’s 
recommendations 
 
2.2.3.5 siRNA deprotection and annealing 
siRNAs that were purchased from Dharmacon were deprotected prior to use. 
Deprotection was performed by resuspending the appropriate amount of siRNA in RNA 
deprotection buffer (2.1.3 No. 3) and incubation at 60°C for 30 min. Subsequently the 
deprotection buffer was evaporated (freeze drying or speed vac) and the siRNAs 
resuspended in PBS. For annealing equal amounts of siRNA sense and antisense strand 
were mixed and heated to 70°C for 5 min and subsequently incubated at 37°C for 60 
min.  
 
2.2.3.6 Quantitative real time RT-PCR analysis (qPCR) 
Gene silencing was assessed by quantitative RT-PCR (qRT-PCR), with a Lightcycler 
Faststart DNA Master SYBR Green I (Roche) and a Roche Lightcycler 1.0 system. The 
reaction volume was 20 µl. Primers for human GAPDH: GAPDH forward, 5’-CTC 
ACT GGC ATG GCC TTC CGT G-3’; GAPDH reverse, 5’-GTA CTC CAG GTG 
GTG GGA CAA CG-3’. Primers for EEF2: EEF2 forward, 5’- ATG GTG AAC TTC 
ACG GTA GAC-3’; EEF2 reverse, 5’-GAC TTG ATG GTG ATG CAA CGG ACT 
TGA TGG TGA TGC AA CG-3’. Briefly, 1-3 x 104 LNCaP cells were seeded in 96-
well plates and incubated overnight at 37°C. Cells were transfected the following day 
with 200 nM non-silencing siRNA or varying amounts of siRNA (10–300 nM for 
siEEF2 sequences 1 and 2) using RNAifect Reagent (Qiagen) following the 
manufacturer’s recommendations. Cells were lyzed after 12 h. Total RNA was extracted 
using the NucleoSpin® RNA II kit (Machery Nagel) and treated with DNase I 
(Machery Nagel). RNA was eluted with 30 µl of RNase free water. Equal amounts of 
RNA were used for cDNA synthesis using random hexamer primers and Superscript III 
RNA polymerase (Invitrogen) following the manufacturer’s recommendations. 
Appropriate amounts of cDNA (2 µl) were used for qRT-PCR. The relative amount of 
target gene mRNA was normalized to GAPDH mRNA by the “delta delta Ct method”. 
Amplification specificity was verified by melt curve analysis.  
 
2.2.3.7 Western blot analysis 
All transfections were performed using RNAifect (Qiagen) following manufacturer’s 
recommendations. Briefly, LNCaP cells (2 x 105 cells/well) were seeded in 12-well 
plates and grown overnight. siRNAs targeting EEF2 or MAPK1 (Qiagen) were 
transfected using RNAifect (Qiagen) at 100 nM. For protein knock down analysis cells 
were harvested after 24h. Cells were washed twice with 1xPBS and lysed using NP-40 
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(GE Healthcare) following manufacturer’s recommendations. 30 µg of soluble protein 
was separated on a 12 % SDS gel (2.2.2.2) electrotransferred to a nitrocellulose 
membrane and analysed by Immunoblotting. EEF2 expression was monitored using a 
polyclonal rabbit ntibody specific for eEF2 (Cell Signaling technologies) and MAKP1 
was detected with monoclonal mouse mAB Tag 100 antibody (Qiagen) both used  
according to manufactures recommendations.  
 
2.2.3.8 Cell viability assay 
Cell viability was assayed using the Cell Proliferation Kit II (XTT) (Roche Applied 
Sciences, Mannheim, Germany). Briefly, cells were seeded in 96-well plates (Greiner) 
at a density of 1-3 x 104 cells per well in 50 µl RPMI 1640 medium, and allowed to 
attach over night at 37°C. Transcripts or siRNAs were added in various final 
concentrations in triplicates (100 µl final volume per well). After 48 h, 50 µl of XTT 
reaction solution was added (sodium 3’-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-
bis(4-methoxy-6-nitro)benzenesulfonic acid hydrate and N-methyl dibenzopyrazine 
methylsulfate). After a 6 h incubation, the optical density at 405 nm was measured 
using an ELISA plate reader. 
2.2.4 Methods for the preparation of RNA aptamers  
2.2.4.1 Isolation of Plasmid DNA from E. coli 
Mini scale plasmid DNA (5 - 20 µg)was isolated using QIAprep® Plasmid Isolation 
Mini Kit according to the manufacturers’ recommendations. Plasmid Maxi Preparations 
were performed using the Pure Yield Promega Maxiprep System (Promega) according 
to manufactures recommendations. Quality of DNA was confirmed by analytical 
agarose gelelectrophoresis (2.2.2.1). Quantity and concentration was determined 
spectrophotometrically (2.2.4.9). Isolated DNA samples were stored at -20°C. 
 
2.2.4.2 Restriction endonuclease digest of plasmid DNA 
Linear plasmid DNA was generated by restriction endonuclease digest. A standard 150 
µL reaction contained:   100 µg Plasmid DNA    
     15 µL  Restriction endonuclease (NEB) 
  
     15 µL  10x EcoRI buffer 
     20 µL  H2O 
The raction was incubated at 37°C for 3h and then the enzyme was heat inactivated at 
65°C for 20 min. Following the DNA was recovered by ethanol precipitation (2.2.4.7) 
and resuspended in H2O.  
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2.2.4.3 Assembly polymerase chain reaction 
DNA templates of the monovalent aptamer siRNAs were generated by assembly PCR 
using four overlapping primers. In the first step of this procedure a small amount of full 
length DNA was produced. In the second amplification reaction using flanking primers 
full length DNA was amplified (Fig. 2.1). 
 
Fig. 2.1:  Scheme of assembly PCR reaction 
Primers were designed by a web based design algorithm that was available online (111): 
Assembly PCR oligo maker 
http://publish.yorku.ca/~pjohnson/AssemblyPCRoligomaker.html 
Following components were used for a 50 µL assembly PCR reaction 
Tab. 2.10:  Components and concentrations of an assembly PCR reaction 
Component Final concentration 
10x PCR buffer 1x 
dNTP 0.2 µM of each four dNTPs 
each of four assembly primers 0,3 µM 
Taq polymerase 0.0125 U/µL 
The following protocol was applied:  
Tab. 2.11:  PCR protocol for an assembly PCR  
  temperature [°C] time [min] step  
1. 95 3 initial denaturation  
2. 95 1 denaturation 
3. 54 1 primer annealing 
4. 72 1 elongation 
 
     10 cycles 
5. 72 5 final elongation  
 
 
 
 
For the second PCR 1µL of the assembly PCR reaction mixture was used as template 
for the amplification reaction which was set up according to (2.2.4.4). 
 
2.2.4.4 Polymerase chain reaction 
DNA templates for the in vitro transcription of monovalent aptamer siRNA constructs 
were generated by standard polymerase chain reaction (PCR). A standard reaction was 
performed in 100 µL volume and contained following components: 
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Tab. 2.1:  Polymerase chain reaction composition 
Component Final concentration 
Template DNA 1 ng 
10x PCR buffer 1x 
dNTP 0.2 µM of each four dNTPs 
5’ forward primer 1 pmol/µL 
3 backward primer 1 pmol/µL 
Taq polymerase 0.025 U/µL 
The following PCR protocol was applied for the amplification reaction:  
Tab. 2.2:  PCR amplification protocol 
 temperature [°C] time [min] step  
1. 95 3 initial denaturation  
2. 95 1 denaturation 
3. Tanneal 1 primer annealing 
4. 72 1 elongation 
 
     25 cycles 
5. 72 5 final elongation  
The optimal primer annealing temperature was determined experimentally (by 
temperature gradient PCR) as the highest annealing temperature at which the PCR 
reaction still worked with good amplification rates.  
 
2.2.4.5 DNA sequence analysis 
DNA sequencing reactions were based on the Dideoxy-chain-termination- method 
described by Sanger et al. Fluorescent labeled dideoxynucleotides were used for 
sequencing of genes or DNA fragments of interest. Sequencing analysis was performed 
by using an “ABI Prism 3700” Capillary-Sequencer (Applied Biosystems) and 
BigDye™ cycle sequencing terminator chemistry. The extension products were detected 
by exciting the unique dyes attached to each dideoxynucleotide with a laser, followed 
by a measurement of fluorescent emission using a CCD camera. 
Subsequently, the signals were interpreted by the Applied Biosystems Sequencing 
Analysis Program in order to determine the nucleotide sequence of the DNA template. 
Resulting chromatograms and sequences were analyzed with the DNA-Star software (). 
 
2.2.4.6 Phenol chloroform extraction  
Phenol chloroform extraction was performed for the removal of protein impurities of 
nucleic acid solutions. An equal volume of phenol was added to the nucleic acid 
solution and the mixture was vortexed for 10 sec. After centrifugation (1 min max 
speed.) the upper phase is transferred to a new tube and two volumes of chloroform 
were added and the mixture was vortexed for 10 sec. After centrifugation (1 min max. 
speed) the upper phase is transferred to a new tube and the nucleic acid is recovered by 
ethanol precipitation (2.2.4.7). 
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2.2.4.7 Ethanol precipitation 
Ethanol precipitation was used to increase the concentration of for recovery of DNA 
fragments from PCR reactions (2.2.4.4) or restriction endonuclease digestion (2.2.4.2) 
or RNA from in vitro transcription (2.2.4.8) or labelling reactions (2.2.4.11). 1/10th 
volume of 3M NaOAc pH: 5,4 were added to the nucleic acid solution and then 2.5 
volumes of pure ethanol were added. After vortexing the mixture is incubated at -80°C 
for 15 min and subsequently centrifuged at 6°C for 15 min at max. speed. The pellet 
was washed with 150 µL 70% ethanol and centrifuged again for 5 min. After the pellet 
was dried at rt for 5 min it was resuspended in H2O (it was important not to “overdry” 
the pellet since this causes the nucleic acid to become insoluble). 
 
2.2.4.8 In vitro transcription reaction 
The aptamer (xPSM-A10-3) and the monovalent aptamer-siRNA transcripts (xPSM-
A3-siEEF2 and xPSM-A3-siGFP) were synthesized by in vitro transcription from a 
double-stranded DNA template bearing a T7 RNA polymerase promoter. The bivalent 
transcripts xPSM-B1 and xPSM-B2 were synthesized by run-off transcription from 
linearized plasmids. Transcriptions were performed in a 20-µl reaction volume using the 
DuraScribe T7 Transcription Kit (Epicentre, Madison, WI) and contained 2 µg DNA 
template, 5 mM ATP and GTP, 5 mM 2’F dCTP and dUTP, and 2 µl of DuraScribe T7 
Enzyme Mix. Reactions were carried out overnight at 37°C and afterwards treated with 
DNaseI for 15 min at 37°C. The RNA products were purified by denaturing (7 M urea) 
gel electrophoresis on an 8% polyacrylamide gel (2.2.2.3). RNA bands were excised 
and RNA was eluted in 0.3 M sodium acetate for 1 h at 60°C and recovered by ethanol 
precipitation (2.2.4.7). 
 
2.2.4.9 Photometric concentration determination of nucleic acid solutions 
For spectrophotometrical analysis of DNA or RNA a 1 to 100 dilution of the nucleic 
acid solution was prepared in water. The OD 260 was determined and the concentration 
was calculated according the following formula: 
µg/ml of nucleic acid  = OD260  x  conversion factor  x dilution factor   
conversion factor:  for dsDNA: 50 µg/mL 
for ssRNA: 40 µg/mL 
 
2.2.4.10 Guanosine-5’-O-monophosphothioate (GMPS) initiator nucleotide 
labeling of RNA 
Transcription reactions were carried out as described above (2.2.4.8) but the NTP 
concentration was lowered to 2.5 mM and the reaction was supplemented with a tenfold 
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concentration (25 mM) of GMPS, to ensure efficient incorporation of the initiator 
nucleotide into the RNA. 
 
2.2.4.11 Fluorescence labelling of RNA  
A standard labeling reaction of 50 µL reaction volume contained approx 1,5 nmol of 
GMPS labeled transcript, 10 mM EDTA, 1 M urea, 100 mM Tris-HCl (pH 7,4), 0.5 
mg/ml 5’ Iodoacetamidofluoresceine and 10% v/v dimethylformamid (DMF) in a final 
reaction volume of 50 µl. The reaction was incubated at 4°C in the dark overnight. 
Labeled transcripts were purified by ethanol precipitation, washed several times with 
70% ethanol and then resuspended in diethylpyrocarbonate (DEPC)-treated water 
 
2.2.4.12 RNA secondary structure prediction analysis 
For the RNA secondary structure prediction the RNA secondary structure prediction 
algorithm MFOLD (http://bioweb.pasteur.fr/seqanal/interfaces/mfold-simple.html) was 
used to predict the secondary structures of aptamer xPSM-A10-3, and aptamer-siRNAs 
xPSM-A3-siEEF2, xPSM-A3-siGFP, xPSM-B1-siEEF2, xPSM-B2-siEEF2 (Fig. 1). 
The negative control xPSM-non was designed accordingly. The most stable structures 
with the lowest free energies for each construct were compared. 
 
2.2.5 Aptamer-siRNA transcript evaluation 
2.2.5.1 Flow cytometric binding analysis 
PSMA expression or Aptamer binding to PSMA positive and PSMA negative cell lines 
was determined via flow cytometry. The anti PSMA specific antibody 3C6 (Northwest 
Biotherapeutics) was used in a dilution of 1/500 in 1x PBS. As secondary antibody a 
GAM-FITC labelled antibody was used in a dilution of 1/500. Prior to analysis cells 
were scraped and washed with PBS. Then 2x105 cells were incubated with primary 
antibody in 500 µL PBS on ice for 30 min. Cells were washed and incubated with 
secondary GAM-FITC antibody on ice for 30 min in the dark. Finally cells were washed 
twice with 1xPBS. Prior to analysis cells were resuspended in 500 µl PBS. Binding 
analysis of FITC-labeled aptamers was performed accordingly at aptamer 
concentrations of 200 nM. Incubation with secondary antibody was omitted.  
In order to dermine the cell viability of a cell population dead cells were stained with 
propidium iodide (PI). Therefore prior to flow cytometric analysis propidium iodide 
was added to the cell suspension at a concentration of 5 µg/mL the solution was 
incubated for 3 min but not longer than 10 min on ice. Dead cells were detected as 
shifted in FL3 direction.  
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2.2.5.2 Cell-surface affinity measurements of aptamer-siRNA transcripts  
LNCaP cells were analyzed using flow cytometry to determine the relative affinities of 
the aptamers xPSM-A3-siEEF2, xPSM-B1-siEEF2 and xPSM-B2-siEEF2 for LNCaP 
cells. The aptamer-siRNAs were first heated to 80°C for 3 min and then incubated at 
37°C for 10 min in 1x HEPES binding buffer (20 mM HEPES, 150 mM NaCl,1 mM 
MgCl2, 1 mM CaCl2, pH 7.4) (2.1.4 No.5). The cells were scraped into microfuge tubes 
and washed with 1.8 ml 1x HEPES binding buffer, then 2–5 x 105 cells were incubated 
for 1 h at 4°C with the FITC-labeled aptamer-siRNAs at concentrations ranging from 
0.02 to 2 µM. Cells were washed twice with 1.8 ml 1x HEPES binding buffer and 
analyzed by flow cytometry. Negative control cell lines were treated as described above 
using aptamer concentrations of 400 nM. Data analysis was performed with CellQuest 
Software (BecktonDickenson). Data represent the average ± SEM out of four 
independent experiments. Each curve was normalized to the maximum MFI obtained.  
 
2.2.5.3 Trypan blue quenching internalization assay 
LNCaP cells (2 x 105) were washed with 500 µl 1 x HEPES internalization buffer (2.1.4 
No. 6) and incubated with 400 nM FITC labeled aptamer-siRNA in 1 x HEPES binding 
buffer supplemented with 16 mM glucose. The “no internalization” controls for each 
transcript were kept on ice. All other samples were incubated in the dark at 37°C for 30 
or 60 min. At the end of the incubation cells were cooled on ice for 5 min. Then cells 
were washed twice and resuspended in 1,4 mg/mL Trypan blue solution in 1x HEPES 
binding buffer. The 100% internalization sample was not treated with Trypan blue 
solution. 
 
2.2.5.4 Internalization assay 
LNCaP cells (2 x 105) were washed with 500 µl 1 x HEPES internalization buffer (2.1.4 
No. 6) and incubated with 400 nM FITC labeled aptamer-siRNA in 1 x HEPES binding 
buffer supplemented with 16 mM glucose. The “no internalization” controls for each 
transcript were kept on ice. All other samples were incubated in the dark at 37°C for 30 
or 60 min. At the end of the incubation cells were cooled on ice for 5 min. In order to 
degrade cell surface PSMA and to remove aptamer-siRNAs bound to PSMA, 0.5 mg/ml 
Proteinase K was added to the cells in 1 x HEPES binding buffer. For the “100% 
internalization” value of each transcript, the Proteinase K treatment was omitted so that 
the maximum amount of internalized transcripts reflected the amount of bound 
fluorescence. After 15 min, cells were collected, washed twice, resuspended in 400 µl 
HEPES binding buffer and analyzed by flow cytometry. For each transcript, data were 
normalized to the untreated samples (100% internalization) and the ones kept at 4°C (no 
internalization).  
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2.2.5.5 Interferon β production assay 
Interferon β secreted into the medium of treated and untreated LNCaP and PC-3 cells 
was detected using a human interferon β ELISA kit following the manufacturer’s 
recommendations (PBL, Biomedical Laboratories). Briefly, LNCaP cells were seeded at 
1-3 x 104 cells/well in 96-well plates and incubated overnight at 37°C. The following 
day, 1 µM aptamer-siRNA was added to the cells and incubated for a further 48 h (final 
volume 150 µl). Then 100 µl of the supernatant was transferred to a precoated ELISA 
plate and incubated for 24 h at room temperature. Interferon β was detected using an 
antibody specific to human Interferon β following the manufacturer’s recommendations. 
 
2.2.5.6 DICER cleavage assay 
Each aptamer-siRNA (25 pmol) was incubated with recombinant human DICER 
overnight at 37°C according to the manufacturer’s recommendations (recombinant 
human DICER kit, Peqlab). Samples were then separated by electrophoresis on a 12 % 
nondenaturing PAGE gel (2.2.2.4). After ethidium bromide staining, bands were 
visualized using a GELDOCXR Image analyzer (BioRad). 
 
2.2.5.7 Apoptosis assay 
LNCaP cells were analyzed using the Apo-ONE Caspase-3/7 assay (Promega). Briefly, 
cells were seeded in 96-well plates (Greiner) at a density of 1 x 104 cells per well in 100 
µl RPMI 1640 culture medium and allowed to attach over night at 37°C. Transcripts or 
siRNAs were added at 1 µM in triplicates (100 µl final volume per well). After 48 h, 
100 µl of Apo-ONE reagent was added. After an overnight incubation, the optical 
density was measured at 485-535 nm using an ELISA plate reader. Data represent the 
average of triplicates ± SEM. 
 
2.2.6 Antibody-siRNA conjugate preparation 
2.2.6.1 Antibody siRNA conjugation via EDC/NHS activation 
During in vitro transcription reaction (2.2.4.8) RNA was labelled with a 
Guanosinemonophosphate initiatornucleotide by supplementing the corresponding 
transcription reaction with a 10 fold excess of guanosine-monophosphate. In a first step 
of the reaction RNA was activated with a 10 fold molecular excess of ECD and 20 fold 
molecular excess Imidazole for 15 min at room temperature. Then equal molar amounts 
of BSA are added to the reaction mixture and incubation was performed over night at 
4 °C. 
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2.2.6.2 Antibody SPDP/SMCC activation 
For activation of the Ki-4 IgG or Ki-4 scFv with N-succinimidyl-3-(2-
pyridyldithio)propionate (SPDP) or Succinimidyl-4-(N-maleimidomethyl)cyclohexane-
1-carboxylate (SMCC) both crosslinking agents were freshly dissolved to a stock 
concentration of 5 mM in Dimethylformamide.  
A standard small scale activation reaction was performed in a volume of 30 µL. For the 
activation reaction the Ki-4 IgG was rebuffered into siRNA conjugation buffer I (100 
mM Na2HPO4; 150 mM NaCl; 2mM EDTA, pH: 7.4) (2.1.4 No. 7)and 20 to 60 µg of 
Ki-4 IgG were used or 5 to 10 µg Ki-4 scFv. The final antibody concentration in the 
reaction mixture was in the range of 0,6 µg/mL to 3 µg/mL. Subsequently a 30 fold 
molecular excess of SPDP or SMCC was added and the reaction was allowed to stir for 
1h at rt. The excess of SPDP and SMCC was removed by gel filtration chromatography 
using Zeba desalt spin columns (Pierce) or Sephadex G25 spin columns (Roche) 
equilibrated in phosphate reaction buffer according to manufacturers recommendations. 
The resulting activated antibody was used for RNA crosslinking.  
 
2.2.6.3 RNA Periodate oxidation and FITC labelling 
In order to activate the 3’ribose unit of RNA an oxidation reaction was performed. RNA 
was incubated with 10 mM Sodiummetaperiodate (Sigma) in 100 mM NaOAc pH: 5,4 
for one hour at room temperature in the dark. Then an equal volume of 60% Glycerol 
was added and incubation was continued for further 15 min. RNA recovered via ethanol 
precipitation (2.2.4.7) and resuspended in 300 mM NaOAc. FITC labelling was 
performed by incubation with 0,5 mg/mL 5’-Fluoresceinethiosemicarbazide over night 
at 4°C. Excess of unreacted FITC was removed by ethanol precipitation (2.2.4.7). 
 
2.2.6.4 Antibody 2-iminothiolane activation 
Prior to the conjugation reaction a fresh stock solution of 50 mM of 2-Iminothiolane 
was prepared in phosphate conjugation buffer (100 mM Na2HPO4; 150 mM NaCl; 2mM 
EDTA, pH: 8). A standard small scale activation reaction was performed in a volume of 
30 µL. For the activation reaction the Ki-4 IgG and Ki-4 scFv was rebuffered into 
siRNA-conjugation buffer (100 mM Na2HPO4; 150 mM NaCl; 2mM EDTA, pH: 8) 
(2.1.4 No. 8) and 20 to 60 µg of Ki-4 IgG were used (Ki-4 scFv: 5-10 µg). The final 
antibody concentration in the reaction mixture was in the range of 0,6 µg/mL to 3 
µg/mL. Subsequently a 100 fold molecular excess of 2-Iminothiolane was added and the 
raction was allowed to stir for 1h at rt. Subsequently the excess of 2-Iminothiolane was 
removed by gel filtration chromatography using Zeba desalt spin columns (Pierce) or 
Sephadex G25 spin columns (Roche) equilibrated in phosphate reaction buffer 
according to manufacturers recommendations. The resulting activated antibody was 
used for RNA crosslinking 
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2.2.6.5 Antibody FITC labelling 
To prove thiolation of Ki-4 IgG the activated antibody was reacted with the thiol 
reactive fluoresceine derivative 5’-Iodoacedamidofluoresceine (5’-IAF) under reducing 
conditions. To 5 µg of the activated and purified antibody 5’-IAF (stock concentration 
of 5 mg/mL in DMF) was added to a final concentration of 0.5 mg/mL. As reducing 
agent Tris(2-carboxyethyl)phosphine hydrochloride (TECEP) was added to a final 
concentration of 10 mM. The mixture was stirred at rt for 1 h and subsequently 
analyzed via SDS gelelectrophoresis (2.2.2.2).  
 
2.2.6.6 RNA SPDP/SMCC activation 
Both crosslinking agents were freshly dissolved to a concentration of 20 mM in DMF. 
For a standard small scale activation reaction 1 to 2 nmol annealed and deprotected 
siRNA were used in a total reaction volume of 25 µL. The reaction was performed in 
phosphate conjugation buffer (100 mM Na2HPO4; 150 mM NaCl; 2mM EDTA, pH: 
7.4). A 100 fold molecular excess of SPDP or SMCC was added and the reaction was 
allowed to stir for 1h at rt. Subsequently the excess crosslinking agent was removed by 
gel filtration chromatography using centrispin 10k spin colums equilibrated in siRNA 
conjugation buffer according to manufacturers recommendations. 
 
2.2.6.7 RNA 2-Iminothiolane activation 
A standard small scale reaction was performed in 25 µL volume. Approximately 1 to 2 
nmol siRNA were used. Immediately before use 2-Iminothiolane was dissolved in 
phosphate conjugation buffer to a concentration of 50 mM. A 500 fold molecular excess 
of 2-Iminothiolane was added and the reaction was allowed to stir for 1h at rt. 
Subsequently the siRNA was precipitated by ethanol resuspended in 25 µL phosphate 
conjugation buffer and further purified by gel filtration chromatography using centrispin 
10k spin colums equilibrated in siRNA conjugation buffer according to manufacturers 
recommendations. 
 
2.2.6.8 RNA FITC labelling 
To prove thiolation of siRNA the activated siRNA was reacted with the thiol reactive 
fluoresceine derivative (5’-IAF) under reducing conditions. To 0,25 µg of activated 
siRNA 5’-IAF (stock concentration of 5 mg/mL in DMF) was added to a final 
concentration of 0.5 mg/mL. As reducing agent Tris(2-carboxyethyl)phosphine 
hydrochloride (TECEP) was added to a final concentration of 10 mM. The mixture was 
stirred at rt for 1 h and subsequently analyzed via native PAGE electrophoresis 
(2.2.2.4). 
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2.2.6.9 Antibody siRNA crosslinking 
Ki-4 IgG-siRNA crosslinking was achieved by mixing SPDP or SMCC activated 
antibody (2.2.6.2) with 2-Iminothiolane activated siRNA (2.2.6.7). If the siRNA was 
activated with SPDP or SMCC (2.2.6.6) it was mixed with 2-Iminothiolane activated 
antibody (2.2.6.4). For a standard crosslinking reaction the siRNA was added in a 5 to 
10 fold molecular excess over Ki-4 IgG. They contained 20 to 60 µg activated antibody 
and 1 to 2 nmol activated siRNA in phosphate conjugation buffer in a total volume of 
70 µL. The reactions were performed in phosphate conjugation buffer at room 
temperature over night for at least 16 h. Subsequently the success of the reaction was 
analyzed via native PAGE electrophoresis (2.2.2.4). 
2.2.7 Antibody siRNA conjugate characterization 
2.2.7.1 Antibody-siRNA quantification  
The concentration of the resulring antibody-siRNA conjugate solution was determined 
according to the Bradford protein quantitation method. As calibration standard purified 
bovine serum albmin (BSA) was used (112). 
 
2.2.7.2 Binding assays 
Ki-4-siRNA conjugate binding activity was determined by flow cytometry. Briefly 
1x105 L540cy cells were washed and incubated with approximately 1 µg Ki-4-siRNA 
conjugates in 400 µL phosphate buffered saline at 4°C for 1h. Then cells were washed 
and incubated with 1 µg FITC-labelled goat anti mouse antibody as a secondary 
detection antibody. Prior to flow cytometric analysis cells were washed twice and 
resuspended in 400 µL phosphate buffered saline.  
 
2.2.7.3 Cell viability assays 
Cell viability was assayed using the Cell Proliferation Kit II (XTT) (Roche Applied 
Sciences, Mannheim, Germany). Briefly, L540cy cells were seeded in 96-well plates 
(Greiner) at a density of 1-3 x 104 cells per well in 50 µl RPMI 1640 medium. Ki-4-
siRNA conjugates were added in 300 nM final concentration in triplicates (100 µl final 
volume per well). After 48 h, 50 µl of XTT reaction solution was added (sodium 3’-[1-
(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzenesulfonic acid 
hydrate and N-methyl dibenzopyrazine methylsulfate). After a 6 h incubation, the 
optical density at 405 nm was measured using an ELISA plate reader. 
 
 
  
3 Results 
3.1 Characterization of siRNA targeting eucaryotic elongation 
factor 2 (EEF2) 
3.1.1 Transfection efficiency 
For the evaluation of new siRNA sequences it is of primary importance to develop 
efficient and reliable transfection protocols in order to achieve the highest gene 
silencing effects possible. For the transfection of siRNAs into eukaryotic cell lines 
many transfection protocols and reagents have been developed. Several companies have 
published optimized siRNA transfection protocols for various cell types and cell lines 
on their websites (Qiagen: http://www1.qiagen.com/Transfection/CellListList.aspx; 
Dharmacon:http://www.dharmacon.com/prodinfo/default.aspx?content=productinfo_pr
otocols). Transfection efficiencies were determined by flow cytometry. Therefore FITC 
labelled siRNAs were transfected at a concentration of 200 nM with different 
transfection protocols. After 12 h of incubation cells were washed twice and the relative 
amount of shifted cells in channel FL-1 in G1 was monitored via flow cytometry. For 
the best protocols the results obtained were further confirmed by fluorescence 
microscopy.   
 
 
 
 
 
  100 µM 
Fig. 3.1: Analysis of transfection efficiencies by fluorescence microscopy (2.2.3.2). LNCaP cells were 
transfected with FITC labeled siRNA at a concentration of 200 nM using RNAifect (2.2.3.1). 
12 h post transfection cells were washed and analyzed visually. A LNCaP cells under 
transparent light  B LNCaP cells under green fluorescent light C overlay of A and B. specific 
intracellular FITC staining was detected .  
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Fig. 3.1 exemplary shows the transfection of 200 nM FITC labelled siRNA into LNCaP 
cells. After 12 h more than 90 % of LNCaP cells were stained by the labelled siRNA 
indicating a high transfection efficiency. Most of the cell lines used could be transfected 
efficiently with RNAifect (Qiagen) a cationic lipofection reagent. The amount of 
RNAifect solution however had to be increased to 1,5 µL per well of a 96 well plates. 
Tab. 3.1 summarizes the transfection efficiencies obtained. L540 hodgkin lymphoma 
cells could not be transfected by any protocol applied. Here different strategies have to 
be pursued in the future. 
Tab. 3.1:  Transfection efficiencies obtained for various cell lines 
cell line  Transfection reagent Protocol Transfection efficiency 
LNCaP RNAifect standard > 90 % 
PC-3 RNAifect standard > 90 % 
MCF-7 RNAifect standard > 90 % 
L293-t RNAifect standard > 90 % 
L540 RNAifect standard < 10 % 
 
3.1.2 Establishment of a q-PCR protocol for EEF2 mRNA expression 
In contrast to antisense ODNs which inhibit the expression of a certain target protein by 
steric hindrance siRNAs induce gene silencing through the degradation of target mRNA 
(113). Therefore the evaluation of expression levels of target mRNAs results in valuable 
information about siRNA efficacy. For the evaluation of mRNA expression levels 
quantitative real time RT-PCR (qPCR) was the method of choice.  
A qPCR protocol has been established for the EEF2 mRNA expression analysis in 
cancer derived cell lines. Gene specific primers flanking the predicted siRNA cleavage 
site were synthesised according to common primer design standards for qPCR 
applications. Product length of the expected PCR product was 221 bp. In order to assure 
a high degree in gene specific amplification both primer sequences were analyzed for 
potential sequence homology to unrelated genes or sequences by the basic local 
alignment search tool (BLAST; http://www.ncbi.nlm.nih.gov/BLAST ). No significant 
homology to any sequence of the human genome was found.  
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Fig. 3.2: Ethidium bromide stained 2 % (w/v) Agarose gel (2.2.2.1) after RT-PCR using eEF2 specific 
Primers. Total RNA was isolated from 2*105 LNCaP cells and cDNA synthesis was performed with 
random hexamer primers (2.2.3.4). 1 µL of cDNA synthesis reaction was used as template DNA for 
subsequent PCR amplification (2.2.4.4). Lane 2: A PCR product at the length of 220 bp was detected. 
Lane 3: –RT control. No product was formed if 1 µL of isolated RNA were used as template indicating 
that no contaminating DNA was amplified.  
 
The predicted cleavage site of siEEF2 and thus the RT-PCR primer binding sites were 
located close to the 5’ end of the EEF2 mRNA which has a length of approx. 12 kb. 
Hence cDNA synthesis was performed using random hexamers as reverse transcription 
primers because the length limit for oligo dT primers was in the range of 12 to 13 kb. 
Indeed no successful RT-PCR could be performed after oligo dT primers were used for 
cDNA synthesis (data not shown).  
Optimal PCR reaction conditions were determined by systematically varying the 
following parameters starting from a standard PCR protocol (2.2.4.4): annealing 
temperature, primer concentrations, magnesium concentrations, PCR-enhancing 
solutions (betaine and DMSO). Fig. 3.2 shows the results of a representative RT-PCR 
reaction performed according to (2.2.3.6). A specific amplification product of the 
expected length (221 bp) could be detected after 40 PCR cycles indicating that these 
primers were suitable for EEF2 mRNA detection . 
Next we sought to transfer these conditions to the LightCycler ® 2.0 Real-Time PCR 
System. These experiments were performed in close collaboration to the Department of 
Virology at the University Hospital Aachen under the supervision of Dr. Michael 
Kleines.  
For real time PCR analysis it was important to identify conditions in which an 
exponential increase in DNA formation could be detected.  
In a first attempt DNA amplification was monitored using gene specific fluorescence 
hybridization probes. No exponential phase could be detected even though the PCR 
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reaction worked which was indicated by the melt curve analysis showing a single DNA 
product melting at 55°C. (Fig. 3.3.A,B). This was further confirmed by agarose gel 
electrophoresis (data not shown).  
 
Fig. 3.3: qPCR analysis of EEF2 mRNA using gene specific hybridization probes (2.2.3.6).  A 
amplification curve of various samples. No exponential increase of DNA could be observed. B melt curve 
analysis of samples after qPCR. A single DNA product melting at approx 55°C could be detected.  
 
 
Obviously the hybridization probes did not work properly. As shown in Fig. 3.4 all 
qPCR reactions efficiently reached the exponential phase if the DNA formation was 
monitored by nonselective SYBR Green staining.   
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Fig. 3.4: qPCR analysis of EEF2 mRNA expression using the SYBR-Green detection method (2.2.3.6). 
Efficient target DNA amplification could be detected. All samples monitored reached the exponential 
growth phase.   
Since specific amplification of EEF2 mRNA by RT-PCR was demonstrated previously 
unselective staining of non EEF2 related amplification products was not an issue. All 
subsequent experiments in which EEF2 mRNA levels were assayed SYBR-Green 
fluorescence was used for analysis. 
 
3.1.3 Gene silencing efficiency of siEEF2 sequence 1 and 2 
After the protocol for quantitative RT-PCR analysis of EEF2 mRNA levels was 
established the gene silencing activity of two siRNA sequences targeting the EEF2 gene 
were evaluated (indicated as siEEF2-sequence 1 and siEEF2 sequence 2). Both 
sequences were designed by Qiagen according the “HP OnGuard siRNA Design” 
algorithm (http://www1.qiagen.com/Products/GeneSilencing/HPOnGuardsiRNA 
Design.aspx). 
In order to compare the potency of both sequences gene silencing activity was assayed 
in a dose dependent manner. Prior to transfection the synthetic siRNAs were 
resuspended and annealed according to manufactures recommendations. Transfections 
were performed according to (2.2.3.1) in 96 well plates. Both sequences were 
transfected into 2x104 LNCaP cells at concentrations ranging from 300 to 10 nM. After 
12 h incubation at 37 °C cells were harvested and analyzed for EEF2 mRNA expression 
(2.2.3.6).  
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Fig. 3.5: Gene silencing activity of siEEF2 was monitored via quantitative RT-PCR (2.2.3.6). mRNA 
levels were normalized to GAPDH mRNA expression A siRNAs were transfected into LNCaP cells at 
various concentrations (10–300 nM). EEF2-mRNA expression was quantified 12 h post transfection. 
Both sequences induced a dose dependent decrease in EEF2 mRNA levels. Sequence 2 (? ): IC50: 23.0 ± 
1.9 nM; Sequence 1(?): IC50: 76.0 ± 3.7 nM. B transfection of an unrelated siRNA (light grey bar) at 
200 nM into LNCaP cells did not alter EEF2 mRNA expression. Transfection of  siEEF2 seq 2 (grey) and 
siEEF2 seq1 (black) led to potent EEF2 mRNA degradation. Error bars represent SEM. n: 2 
As shown in in Fig. 3.5. both siRNAs induced dose dependent EEF2 mRNA 
degradation (A). Sequence 2 proved to be approximately 3 fold more potent displaying 
an IC50 value of 23.0 ± 1.9 nM compared to sequence 1 with an IC50 of 76.0 ± 3.7 nM. 
The overall efficacies for both siRNAs were essentially equal reaching a maximum 
knock down of EEF2 mRNA of approximately 80 %. In addition transfection of an 
EEF2 unrelated “nonsilencing” siRNA was used as a control and did not cause any 
changes in the EEF2 mRNA level (Fig. 3.5; B) confirming sequence specificity of 
siEEF2. Due to the higher overall potency of sequence 2 this sequence was used for 
subsequent experiments.  
 
3.1.4 Evaluation of EEF2 knock down on protein level 
It is important not only to prove the siRNA mediated knock down of the target mRNA 
but also to monitor knock down of the protein expression levels of the corresponding 
target protein.  
The effect of siEEF2 sequence 2 on the protein expression level of EEF2 was analyzed 
after transfection into LNCaP cells at a concentration of 100 nM. After 24 h cells were 
lyzed and assayed for EEF2 protein expression by western blot analysis using an EEF2 
specific polyclonal anti-EEF2 antibody (Cell Signalling Technologies) (2.2.3.7). As 
positive control a siRNA sequence targeting the ubiquitously expressed mitogen 
activated protein kinase 1 (MAPK1) was also transfected into LNCaP cells and target 
protein expression detected with the MAK1 specific Tag 100 antibody (Qiagen).  
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Fig. 3.6: Western blot analysis of EEF2 protein expression (2.2.3.7). siRNA was transfected into LNCaP 
cells at a concentration of 100nM.  After 24h cells were lyzed using NP-40 and protein expression was 
analyzed  by western blot. Expression of MAPK1 and EEF2 was detected by specific antibodies. A Band 
intensities were quantified using AIDA Image analyzer software. Target protein expression was 
normalized to cells only treated with transfection agent. MAPK1 expression (grey bars) and EEF2 
expression (white bars) is shown. Transfection of siEEF2 and siMAPK1 led to a significant knock down 
of target protein. B Corresponding western blot for MAPK1 and C corresponding western blot for  EEF2. 
 
The bar diagram in Fig. 3.6. shows the relative protein expression of EEF2 and MAPK1 
control respectively analyzed by western blot analysis after transfection of either 
siEEF2 or siMAPK1 into LNCaP cells. The band intensities were quantified by the 
AIDA image analyzer software and were normalized to the band intensities observed 
for the samples only treated with transfection agent (A). White bars represent EEF2 
expression. Grey bars represent MAPK1 expression. Transfection of siRNAs targeting 
MAPK1efficiently reduced MAPK1 protein expression up to approx 85 % whereas 
EEF2 expression was not affected. Upon transfection of siEEF2 a significant reduction 
in EEF2 expression was detectable. However the MAPK1 protein expression level was 
also reduced upon siEEF2 treatment. This result correlated with the expectation that 
efficient knock down of EEF2 should be accompanied by the inhibition of protein 
biosynthesis which in turn affects protein levels of potentially untargeted proteins.  
 
3.1.5 Evaluation of the cytotoxicity of siEEF2 
EEF2 modifying enzymes such as bacterial and plant toxins like Pseudomonas exotoxin 
A (ETA) or ricin are very potent inhibitors of EEF2. Inhibition of EEF2 by these toxins 
leads to the arrest of protein biosynthesis which causes the induction of apoptosis and 
cell death. 
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To examine whether the siRNA mediated depletion of EEF2 leads to the induction of 
cell death the cell viability was analyzed 48 h after transfection of siEEF2. A 
colorimetric cell viability assay based on the activity of mitochondrial enzymes present 
in viable cells was used. siRNA were transfected into various cell lines at 
concentrations ranging from 0,002 to 2µM.  
 
 
 
 
 
10-2.0 10-1.5 10-1.0 10-0.5 100.0 100.5
-5
15
35
55
75
95
MCF-7
LNC 
 
 
 
 
 
 101.0
aP
siRNA [µM]
%
 v
ia
bi
lit
y
 
Fig. 3.7: XTT-Viability Assay of transfected LNCaP(?) and MCF-7 (□) cells (2.2.3.8). Cells were 
transfected with different concentrations of siEEF2 using RNAifect (Qiagen) (2.2.3.1). Cell viability was 
assayed 48h post transfection. Data acquisition was performed after 6h supstrate incubation. Dose-
dependent cytotoxicity was induced by siEEF2 in both cell lines used. The average half maximal 
inhibitory concentration (IC50) was determined as 150 nM in LNCaP cells and 80 nM in MCF-7 cells. 
Data represent the average of triplicate samples ± SEM.  
 
Efficient induction of cell death was observed after siEEF2 transfection in LNCaP as 
well as MCF-7 cells (Fig. 3.7). The IC50 values obtained for these cell lines were 80 nM 
for MCF-7 and 150 nM for LNCaP cells. This result clearly demonstrated that siRNA 
mediated knock down of EEF2 mRNA leads to the inhibition of protein biosynthesis 
and in turn induces cells death in various cell lines.  
 
3.1.6 Summary 
Eukaryotic elongation factor 2 is a central component of the protein biosynthesis 
machinery. The results presented here clearly demonstrate that the siRNA sequences 
targeting EEF2 efficiently induce siRNA mediated knock down of EEF2 mRNA levels 
with EC50 values in the range of 20 to 70 nM. It was also shown that the protein 
expression level of EEF2 was significantly reduced upon transfection of siEEF2.  
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The siRNA mediated knock down of EEF2 efficiently induced cell death in cancer 
derived cell lines.  
Based on these results siEEF2 sequence 2 was the siRNA sequence of choice used for 
for the design and synthesis of bivalent aptamer siRNA transcripts as well as for the 
synthesis of antibody-siRNA conjugates 
 
3.2 Evaluation of aptamer siRNA transcripts   
Design, synthesis and all experiments performed with the monovalent aptamer siRNA 
transcript xPSM-A3-siEEF2 were performed by Dipl.-Bioinf. Inga Neef (Fraunhofer 
IME, aachen). A detailed description of these experiments and results obtained with this 
molecule will be presented in her Ph.D. thesis. The data of xPSM-A3-siEEF2 presented 
here were only for comparative analysis and were not content of the practical work of 
this thesis.    
 
3.2.1 Design of bivalent aptamer siRNA transcripts 
As mentioned before PSMA is constitutively internalized from the cell surface of 
LNCaP cells. The internalization rate of this cell surface receptor can be enhanced upon 
administration of a monoclonal anti PSMA antibody. In analogy it was predicted that 
the internalization rate and thus the efficiency of these aptamer siRNA transcripts could 
be enhanced by increasing their valency by rational design.  
The most important aspect for the design of bivalent aptamer siRNA transcripts is that  
the active conformation of both aptamer moieties was retained. RNA secondary 
structure analysis were performed using the mfold webserver 
(http://frontend.bioinfo.rpi.edu/applications/mfold/cgi-bin/rna-form1.cgi). This server 
computes and predicts the secondary structure of single stranded RNA molecules by 
minimal free energy calculations (48).  
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Fig. 3.8: mfold webserver based RNA secondary structure prediction of the truncated anti-PSMA 
aptamer xPSM-A10-3 (2.2.4.12). The aptamer folds into a stable stem loop structure. The potential 
binding epitope is depicted by the frame and arrow.  
 
The predicted secondary structure of the truncated anti-PSMA aptamer xPSM-A10-3 is 
shown in Fig. 3.8. The aptamer folds into a stable stem loop structure comprising three 
bulges of  one, three and two nucleotides respectively. It has previously been shown that 
the binding epitope is located in the boxed region (ref). Therefore this characteristic 
folding motive had to be retained in the bivalent aptamer siRNA transcripts.  
Extensive folding analysis revealed that it was not possible to place the aptamer 
sequences immediately adjacent to each other because parts of one aptamer hybridized 
to complementary sequences of the other aptamer moiety (data not shown).  
The two aptamer sequences had to be separated by a rigid linker sequence that 
prevented the two aptamers from folding “upon” each other. Highest rigidity in this 
respect is provided by double stranded RNA helices. Therefore the dsRNA helix 
comprised by siRNA portion that had to be incorporated into these transcripts was used 
as a “spacer” sequence. The siRNA sense strand was incorporated between the two 
aptamer sequences and the siRNA antisense strand was added at the 3’ end of the 
second aptamer moiety.  
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Fig. 3.9: Predicted secondary structure of the bivalent aptamer siRNA transcript xPSM-B1-siEEF2 
(structure with the lowest free energy, ΔG, is shown) (2.2.4.12). Both aptamer sequences fold into their 
active conformation (boxes). The siRNA sense strand (siRNA sen) is located between the two aptamer 
sequences upon annealing to the complementary antisense strand of the siRNA (siRNA as) the double 
stranded siRNA “spacer” is formed.  
 
The predicted secondary structure with the lowest free energy of the bivalent aptamer 
siRNA transcript xPSM-B1-siEFE2 is depicted in Fig. 3.9. The difference in free 
energy between the predicted structure with the lowest and highest free energy was -1,2 
kcal/mol (ΔG(max): - 66,1; ΔG(min): -64,9 kcal/mol). This indicated that the minimal 
free energy structure shown here was the structure that dominates at 37°C.  
At this point it was questionable whether the siRNA moiety would be recognized and 
processed by the endogenous RNA interference machinery mainly because nothing was 
known about the processing of more complex RNA structures which did not display 
shRNA characteristics. Therefore a second bivalent aptamer siRNA transcript (xPSM-
B2-siEEF2) was designed which additionally carried a second siRNA sequence 
presented as shRNA that was known to be incorporated into the endogenous RNAi 
pathway (17). 
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Fig. 3.10: Predicted secondary structure of bivalent xPSM-B2-siEEF2. Again the structure with the 
lowest free energy is shown (2.2.4.12). Two siRNA sequences were inserted. One was designes as 
“spacer” (Fig. 3.9) and one of the two siRNA moieties was designed to built a shRNA. Both aptamer 
sequences fold into their potential binding conformation (boxes) .  
 
The design of the bivalent xPSM-B2-siEEF2 was similar to xPSM-B1-siEEF2 except 
that the shRNA domain was inserted at the 3’ end of aptamer 2. The loop sequence of 
the shRNA portion was designed according to Hannon et al. (17). 
 
3.2.2  Assembly PCR of bivalent aptamer siRNA DNA templates 
The initial strategy for the production of bivalent aptamer siRNA transcripts was to 
perform in vitro transcription by using DNA templates that were generated via PCR-
assembly strategies (2.2.4.3).  
The expected DNA products had a length of 190 bp (xPSM-B1-siEEF2) and 243 bp for 
xPSM-B2-siEEF2 respectively. Six overlapping primers covering the sequence of 
xPSM-B1-siEEF2 and xPSM-B2-siEEF2 were designed by the oligo assembly PCR 
maker (http://publish.yorku.ca/~pjohnson/AssemblyPCRoligomaker.html) (111). The 
PCR was performed in two steps. First the assembly PCR was performed with all six 
overlapping primers which should produce small amounts of full length template DNA. 
Then in a second PCR reaction an aliquot of the assembly reaction mixture served as a 
template for the amplification PCR with flanking primers. In this reaction the small 
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amounts of full length DNA product produced in the assembly reaction should be 
amplified.  
 
Fig. 3.11: Ethidium Bromide stained 2% (w/v) Agarose gel (2.2.2.1) of an assembly and an amplification 
PCR of both bivalent aptamer siRNA constructs (2.2.4.3; 2.2.4.4). M: 2Log DNA ladder (NEB) Lane 1: 
assembly PCR of xPSM-B1-siEEF2; Lane 2: amplification PCR of xPSM-B1-siEEF2; Lane 3 assembly 
PCR of xPSM-B2-siEEF2, lane 4 amplification PCR of xPSM-B2-siEEF2. After amplification PCR the 
main amplification product is of smaller than the expected size. Only a very faint band of the correct size 
is visible for both constructs.  
 
In Fig. 3.11 the results of one assembly/ amplification PCR (2.2.4.3) of both bivalent 
aptamer siRNA constructs are shown. Only a very faint band at the expected size could 
be detected whereas the main amplification products of both constructs did not have the 
expected length. Tab. 3.2 shows a summary of parameters that were optimized in order 
to increase the yield of full  length PCR product. 
Tab. 3.2:  Summary of conditions used for assembly PCR 
Strategy/parameter result 
optimization of annealing temperature for assembly PCR poor 
optimization of annealing temperature for amplification PCR poor 
gel purification of assembly PCR reaction poor 
gel purification of amplification reaction followed by an other amplification 
reaction 
poor 
MgCl2 concentration  poor 
TOPO TA cloning of gel purified product band no insert  
 
It was not possible to generate reasonable amounts of full length DNA constructs with 
any strategy applied. The predominant amplification product was always present at a 
length of 100 (xPSM-B1-siEEF2) or 150 bp (xPSM-B2-siEEF2) respectively. Attempts 
for direct TOPO TA cloning of the gel purified faint DNA bands of the correct size 
failed since no positive transformants could be identified. 
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All these results showed that it was not possible to generate full length template DNAs 
of both bivalent aptamer siRNA constructs via assembly PCR strategies. This was the 
reason why finally template DNAs were synthesised via whole gene synthesis 
techniques and cloned into a pUC-19 Vector by Gene Art (Regensburg). 
 
3.2.3 In vitro transcription of bivalent aptamer siRNA transcripts 
RNA transcripts were generated via runoff in vitro transcription using linearized 
plasmid DNA as template. Initially the yields resulting from these runoff in vitro 
transcriptions were rather poor. The reason for that could be found in the template DNA 
preparation method. For these reactions template plasmid DNA was linearized by SacI 
restriction which produces 3’ protruding ends. RNA polymerases however do not 
efficiently dissociate from template DNA that comprises 3’ protruding ends which was 
the reason for the low yields. After plasmid DNAs were linearized by EcoRI the yields 
of in vitro transcription reactions could be raised up to 50 fold. The average yield of a 
standard 20 µL DURASCRIBE transcription reaction performed according to 
(METHODS) was approx 0,4 to 1 nmol RNA. An ethidium bromide stained 8% urea 
PAGE gel is shown in Fig. 3.12..  
 
 
Fig. 3.12: Ethidium bromide stained 8% (w/v) Polyacrylamide urea gel of various RNA samples 
(2.2.2.3). High Century 100 bp RNA Marker was used as size standard  lane 1: xPSM-A10-3 transcribed 
aptamer; lane 2: xPSM-B2-siEEF2 (expected length: 234 nt); lane 3: xPSM-B1-siEEF2 (expected length: 
173 nt). All transcripts could be efficiently in vitro transcribed and corresponding RNA bands were 
detected at the correct length (2.2.4.8).  
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All aptamer siRNA transcripts could be produced by in vitro transcription in good 
yields. RNA integrity and correct transcript length could be confirmed by analytical 
denaturing PAGE gel electrophoresis.   
 
3.2.4 RNA Fluoresceine labeling 
In order to determine the binding affinity and internalization characteristics of aptamer 
siRNA transcripts it was important to establish protocols that allowed for efficient and 
reproducible fluorescence labelling of aptamer siRNA transcripts. Therefore a reactive 
inititiator nucleotide was incorporated into the aptamer siRNA transcripts at the 5’ end 
during in vitro transcription (114). In a second reaction the generated 5’thiol modified 
RNA could be labelled with a thiol reactive fluoresceine derivative 
(5-(Iodoacetamido)fluorescein (5-IAF))(2.2.4.10 and 2.2.4.11). After purification by 
ethanol precipitation (2.2.4.7) the success of the labelling reaction could be monitored 
via analytical urea PAGE gel electrophoresis (2.2.2.3).   
 
 
Fig. 3.13:  8% urea PAGE gel (2.2.2.3) of various FITC labelled RNAs A:  UV- light picture without 
EtBr staining (2.2.4.11). lane 1: xPSM-B2-siEEF2; lane 2: xPSM-B1-siEEF2; 3: xPSM-A3-siEEF2; 4 
xPSM-A10-3; B: Ethidium bromide stain of the same gel shown in A in order to visualize RNA. RNAs 
could be fluorescence labelled by reaction with 5-IAF.  
 
All aptamer siRNA transcripts used for these experiments could be specifically 
fluorescence labeled at their 5’ (Fig. 3.13). Labeling efficiencies were comparable for 
all aptamer siRNA transcripts.  
 
 
Results 61 
3.2.5 Analysis of binding specificity of bivalent aptamer siRNA 
transcripts 
After having established fluorescence labeling techniques the binding characteristics of 
bivalent aptamer siRNA transcripts was investigated. The first experiments addressed 
the question whether the binding specificity of the bivalent aptamer siRNA transcripts 
for PSMA positive cell lines was retained.  
Therefore cell surface binding affinity of xPSM-B1-siEEF2 and xPSM-B2-siEEF2 was 
analyzed on PSMA positive and PSMA negative control cell lines by flow cytometry. 
Two PSMA negative cell lines were analyzed, such as the prostate cancer derived cell 
line PC-3 and the breast cancer derived cell line MCF-7. As PSMA positive cell line 
LNCaP cells were used. Cell surface expression of PSMA was confirmed by flow 
cytometry using the anti PSMA specific monoclonal antibody 3C6 (Northwest 
Biotherapeutics) (2.2.5.2). The resulting Histogram plot is shown in (Fig. 3.14). PSMA 
expression could be confirmed and was restricted to LNCaP cells. MCF-7 cells did not 
show significant binding of the antibody.  
 
 
Fig. 3.14: Binding analysis of the PSMA specific antibody 3C6 (dilution 1/500) (Nothwest 
Biotherapeutics) on LNCaP and MCF-7 cells (2.2.1)(2.2.5.2). As secondary antibody a GAM-FITC 
antibody was used for detection (dilution 1/500). unstained cells are shown in red, antibody is shon in 
green/black A: PSMA expression was proved by the specific binding of the antibody to LNCaP cells B: 
PSMA negative MCF-7 cells were not bound by this antibody.   
 
Binding analysis with the fluorescence labeled bivalent aptamer siRNA transcripts were 
performed as described in (2.2.5.2). The final concentration of FITC labeled aptamer 
siRNA transcripts in these assays was 400 nM. Prior to flow cytometric analysis the 
cells were washed twice and resuspended in 1x HEPES binding buffer. The resulting 
histograms for LNCaP, MCF-7 and PC-3 cells are shown in (Fig. 3.15). 
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Fig. 3.15: Flow cytometric analysis of FITC labeled aptamer-siRNA transcrips (2.2.4.11) on PSMA 
positive and PSMA negative cell lines (2.2.1)(2.2.5.1).  A LNCaP cells: bivalent aptamer-siRNA 
transcripts showed a shift in FL-1 (green, purple). Cell surface membrane staining was confirmed by 
fluorescence microscopy (inset) B, MCF-7 cells: small shift in FL-1 was observed. No membrane staining 
was visible (inset). C PC-3 cells: No shift was detectable for any aptamer construct. 
 
Binding activity of all aptamer-siRNA transcripts was restricted to PSMA-positive 
LNCaP cells (Fig. 3.15,A). In addition cell membrane staining could also be confirmed 
by fluorescence microscopy (inset). In contrast no binding of any of the aptamer siRNA 
transcripts used was observed on the PSMA negative cell lines MCF-7 and PC-3 (Fig. 
3.15, B,C). 
These results clearly demonstrate that the binding specificities of the bivalent aptamer-
siRNAs  for PSMA expressed on the cell surface of LNCaP cells  are comparable to that 
of the monovalent xPSM-A3-siEEF2. 
 
3.2.6 Functional affinity measurements 
As a next step the binding affinity of the mono and bivalent aptamer siRNA transcripts 
was compared. In theory the bivalent transcripts should bind with a higher affinity due 
to positive avidity effects. Here the overall functional affinity to PSMA expressing 
LNCaP cells was analyzed. Therefore 2x105 LNCaP cells were incubated with 
fluorescence labelled aptamer siRNA transcripts at varying concentrations in the range 
of 0,02  µM to 2 µM (2.2.5.2).  
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The observed absolute geometric mean fluorescence intensity in FL-1 varied 
significantly from experiment to experiment. in order to be able to compare data from 
different experiments the observed geometric mean fluorescence in FL-1 at saturating 
transcript concentrations aptamer (2 µM) was set as 100 % mean fluorescence intensity. 
All subsequent mean fluorescence intensities were then converted to the relative mean 
fluorescence intensities. Finally the obtained relative mean fluorescence intensities were 
plotted against the logarithmic transcript concentration.  
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Fig. 3.16: Functional affinity (2.2.5.2) of FITC labeled aptamer siRNA transcripts (2.2.4.11) to LNCaP 
cells (2.2.1) were determined. Cells were incubated with varying transcript concentrations (0,02 to 2 µM) 
and analyzed via flow cytometry. geoMFI was normalized to the maximal geo-MFI obtained at saturating 
aptamer concentrations. The obtained functional kD for xPSM-A3-siEEF2 was 0.81 ± 0.1 µM. For xPSM-
B1-siEEF2 and xPSM-B2-siEEF2 values of 0.44 ± 0.02 µM and 0.38 ± 0.08 were obtained. Each curve 
represents the average out of three independent experiments. Error bars represent ±SEM. 
 
A dose dependent decrease in the relative geo-MFI was obtained for all aptamer siRNA 
transcripts (Fig. 3.16). The monovalent xPSM-A3-siEEF2 showed a functional affinity 
constant of kD: 0.81 ± 0.1 µM which was roughly two fold higher compared to bivalent 
xPSM-B1-siEEF2 (0.44 ± 0.02 µM) and sPSM-B2-siEEF2 (0.38 ± 0.08 µM). The 
observed kD values were statistically analyzed by using the two way ANOVA test 
(analysis of variancys). For both bivalent transcripts a p value p< 0,05 was obtained 
indicating that the observed differences were statistically significant.  
Unfortunately these results could not be further corroborated with kinetic analysis for 
instance by using the Biacore technology, since purified PSMA was not available and 
no binding could be shown on immobilized LNCaP membrane fractions (data not 
shown). 
At this point it is noteworthy that all incubation steps during the functional affinity 
measurements were performed at 4°C. At this temperature receptor mediated 
endocytosis is largely inhibited so that only the binding affinity was assayed. 
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3.2.7 Internalization assays 
In order prove the hypothesis that bivalent aptamer siRNA transcripts were taken up 
more efficiently by LNCaP cells compared to their monovalent counterpart, 
internalization assays were performed. Beforehand however the best assay conditions 
had to be determined. 
Since internalization had to be examined in a quantitative and comparative manner it 
was not possible to apply fluorescence microscopy techniques. Different radioactive or 
flow cytometry based assay formats were tested in order to identify conditions in which 
internalization could be assayed in high accuracy and reproducibility. It turned out that 
radioactive assay formats were not applicable because the sample to sample deviation 
was too high (data not shown). However it became clear that the efficient removal of 
remaining cell surface bound aptamers was a prerequisite for the correct interpretation 
of internalization experiments. Removal of bound aptamers by an acidic glycine 
(pH:2,7) wash buffer commonly used for the removal of cell surface bound antibodies 
did not work even under stringent washing conditions (data not shown) (115). 
For the flow cytometric internalization assays cells were incubated with FITC labeled 
aptamer siRNA transcripts. The basic set up is described in (2.2.5.3). Nevertheless the 
exclusion of fluorescence resulting from cell surface bound aptamers was a very 
important. In a first attempt it was tried to quench cell surface bound fluorescence by 
the addition of Trypan blue solution according to Stish et al. (116).  
 
 
Fig. 3.17: Dotplot of LNCaP cells (2.2.1) stained with 400 nM FITC labeled aptamer xPSM-A3 
(2.2.5.1)(2.2.5.3). A cells without Trypan blue solution. Approx 51 % of the gated cells were shifted in 
the FL-1 channel. B cells with Trypan blue solution. Approximately 42 % of the gated cells were shifted 
in the FL-1 channel. 
 
Fig. 3.17 shows the results of these Trypan blue quenching experiments. After the 
excess of FITC labeled aptamer was removed the cells were resuspended in 1,4 mg/mL 
Trypan blue quenching solution. A significant decrease in the absolute fluorescence 
intensity in the FL-1 channel was detected upon Trypan blue quenching. However the 
relative number of shifted cells in FL-1 was only reduced by 10%. These results showed 
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that it was not possible to apply this assay format because fluorescence quenching of 
cell surface bound FITC labeled aptamers was too inefficient.  
Next it was tried to remove cell surface bound aptamers via Proteinase K treatment. 
Proteinase K is a non specific serin-protease that displays high activity even at low 
temperatures. It has been shown that cell surface bound ligands can be removed via 
Proteinase K mediated degradation of cell surface proteins (117,118).  
As a first experiment it was analyzed if the cells would tolerate Proteinase K treatment. 
After prolonged incubation of LNCaP cells with Proteinase K the cell population was 
analyzed for potential toxic effects by propidium iodide (PI) staining.  
 
 
Fig. 3.18: Flow cytometric analysis of LNCaP cells (2.2.1) after 30 min incubation with 0,5 mg/mL 
Proteinase K (2.2.5.4). Cell viability was assayed by the incubation with propidium iodide prior to 
analysis (2.2.5.1) A Forward sideward scatter B FL-1/FL-3 dotplot after propidium iodide staining. The 
main population was not stained by PI indicating that Proteinase K treatment was not toxic. 
 
No significant toxicity was induced by Proteinase K incubation since only a minor 
fraction of LNCaP cells was stained by PI (18 %) (Fig. 3.18).  
Finally it was analyzed whether Proteinase K treatment efficiently removed cell surface 
bound aptamer siRNA transcripts. LNCaP cells were incubated on ice (no 
internalization) with 400 nM FITC labeled aptamer siRNA transcrips for 1 h. After 
Proteinase K treatment (0,5 mg/mL for 15 min on ice)  cells were washed twice 
resuspended in 1x binding buffer and analyzed by flow cytometry. As shown in (Fig. 
3.19) Proteinase K treatment almost completely removed cell surface bound 
fluorescence (green, purple). Therefore this protocol proved to be suitable for the 
application in quantitative and comparative internalization assays. 
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Fig. 3.19: Histogram plot of LNCaP cells (2.2.1) stained with 400 nM FITC labeled monovalent xPSM-
A10-3 with (2.2.4.11) (green, purple) or without subsequent Proteinase K treatment (2.2.5.4). Proteinase 
K efficiently removed cell surface bound aptamers via proteolytic degradation of PSMA.  
 
Previous studies dealing with the antibody induced internalization of PSMA 
demonstrated that PSMA uptake reached a plateau within one hour. Based on this study 
internalization was monitored within this time frame at two time points (30 and 60 min).  
The amounts of transcript that were internalized at 37°C was determined by the 
percentage of cells that were shifted in FL-1 (FITC) direction and could be detected in 
gate 1. Each sample was normalized to the “no-internalization control” which was kept 
at 0°C and served as the reference (0% value). The “binding control” sample that was 
not treated with Proteinase K was set as the 100% internalization value (Fig. 3.20). 
 
 
Fig. 3.20: Example how data analysis for the internalization assays was performed (2.2.5.4). A Dotplot of 
unstained LNCaP cells treated with Proteinase K B Dotplot of gated LNCaP cells (2.2.1) incubated with 
aptamer siRNA transcript and kept at 4°C (“no internalization control”). C Cells shifted and detected in 
gate 1 were shown. Cells stained with FITC-labelled aptamer but not treated with Proteinase K were set 
as the 100% internalization value.  
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The results of these experiments are shown in Fig. 3.21. 
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Fig. 3.21: Flow cytometric internalization assay (2.2.5.4). FITC labeled aptamer siRNA transcripts were 
incubated with LNCaP cells (2.2.1) at 37°C for 30 and 60 min. After removal of cell surface bound 
transcripts by Proteinase K treatment the relative amount of  internalized aptamer siRNA transcripts was 
determined. After 30 min 17% and after 60 min 32 % of the initially bound bivalent transcript was 
internalized (white bars) whereas only 5% (30 min) respectively 8% (60 min) of the monovalent xPSM-
siEEF2 was internalized. Average values from three independent experiments are shown. Error bars 
represent SEM. 
 
A time dependent increase in internalization could be detected for both aptamer siRNA 
transcripts. The bivalent xPSM-B2-siEEF2 showed a significantly higher uptake at both 
time points assayed. After 30 min 17,4 ± 0.3% and after 60 min  32.1 ± 3.7% of initially 
bound xPSM-B2-siEEF2 were internalized. Only 5.5 ± 2.6% (30 min) respectively 8,46 
± 5.6%  (60 min) of the monovalent xPSM-A3-siEEF2 were taken up by PSMA 
positive LNCaP cells.  An unpaired students t-test resulted in p-values p<0,05 at both 
time points indicating that the differences obtained were statistically significant.  
These results clearly demonstrate that the bivalent aptamer siRNA transcripts are taken 
up much more efficiently compared to the monovalent construct apparently due to 
avidity effects.  
 
3.2.8 In vitro DICER assays 
The next step was the characterization of the second functionality present in the 
bifunctional molecules xPSM-B1-siEEF2 and xPSM-B2-siEEF2, the siRNA portion.  
McNamara et al. showed that their aptamer siRNA chimeras could only enter the RNAi 
pathway and trigger posttranscriptional gene silencing after being processed by 
endogenous DICER. Since the chimeras presented in this study were very similar to the 
monovalent x-PSM-A3-siEFE2 it seemed to be likely that the bivalent transcripts also 
had to be processed by DICER to result in active siRNAs. In order to prove this 
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hypothesis in vitro DICER cleavage assays were performed using recombinant human 
DICER enzyme (Fig. 3.22). Equimolar amounts of aptamer siRNA transcripts were 
subjected to in vitro DICER processing (2.2.5.6).  
 
Fig. 3.22: In vitro DICER cleavage assay (2.2.5.6). Equimolar amounts of RNA were incubated with 
recombinant human DICER enzyme. Cleavage products were resolved on a nondenaturing 12% PAGE 
gel. Resulting bands were ethidium bromide stained. All aptamer siRNA transcripts serve as DICER 
substrates.   
 
After electrophoretic separation of cleavage products it could be shown that the bivalent 
aptamer siRNA transcripts serve as DICER substrates and are processed into fragments 
of approximately the size of an active siRNA (21 – 27 bp).  
 
3.2.9 Evaluation of the cytotoxic potential of the bivalent constructs 
x-PSM-B1-siEEF2 and x-PSM-B2-siEEF2 
In chapter 3.1.5 it was shown that the transfection of siEEF2 induced EEF2 mRNA 
degradation which finally caused the induction of cell death.  
For the bivalent aptamer siRNA transcripts it was investigated whether the siRNA 
portion of xPSM-B1-siEEF2 and xPSM-B2-siEEF2 would be processed into functional 
siRNA molecules that could elicit the RNA interference mediated degradation of EEF2 
mRNA. In analogy to the results obtained for the transfected siRNAs it was predicted 
that the bivalent aptamer-siRNAs would be taken up by LNCaP cells and induce cell 
death by siRNA mediated EEF2 mRNA degradation.  
To test this hypothesis in vitro cell viability assays were performed. In a first 
experiment the antigen specificity of xPSM-B1-siEEF2 and x-PSM-B2-siEEF2 was 
investigated. PSMA positive LNCaP as well as PSMA negative PC-3 and MCF-7 cells 
were incubated with aptamer siRNA transcripts at a concentration of 2 µM in the 
absence of transfection agent at 37°C for 48 h. Subsequently cell viability was 
determined as described in (2.2.3.8). 
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Fig. 3.23: XTT viability assay (2.2.3.8) after 48 h incubation of 2 µM bivalent aptamer siRNA transcripts 
on PSMA negative MCF-7 (grey bars) and PC-3 cells (white bars) and on PSMA positive LNCaP cells 
(black bars)(2.2.1). Cytotoxic effects caused by xPSM-B1-siEEF2 and xPSM-B2-siEFE2 were restricted 
to the PSMA positive cell line. At a transcript concentration of 2 µM viability was reduced up to 95%. 
Mean values of triplicate experiments are shown (n:4, ± SEM). 
 
 
These results of these experiments clearly demonstrated that both bivalent aptamer 
siRNA transcripts (xPSM-B1-siEEF2 and xPSM-B2-siEEF2) efficiently induced cell 
death in PSMA expressing LNCaP cells (black bars) and that these effects were cell 
type selective since PSMA negative cell lines were not affected (Fig. 3.23). 
In order to exclude that the observed effects were caused by non sequence specific 
effects as a result to uptake of complex RNA molecules an other negative control 
aptamer was incorporated in these experiments. A bivalent negative control aptamer 
siRNA transcript was designed (xPSM-B2-non) (3.2.1). In this molecule the siRNA 
sequences targeting EEF2 were replaced by two non EEF2 related siRNAs. Besides that 
the inserted siRNA sequences did not comprise homology to any known human gene or 
sequence and thus were “nontargeting”. The overall structure according to mfold 
analysis was equal to that predicted for xPSM-B2-siEEF2 ( 
Fig. 3.10). Accordingly binding and uptake characteristics were also the same for 
xPSM-B2-non (data not shown).  
When applied to LNCaP cells at a concentration of 2 µM this aptamer siRNA transcript 
did not induce toxic effects whereas both bivalent transcripts reduced the cell viability 
by up to 95% (Fig. 3.24). This result clearly showed that the observed cytotoxic effects 
can be addressed to siRNA portion targeting EEF2.  
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Fig. 3.24: XTT viability assay (2.2.3.8) of LNCaP cells (2.2.1) incubated for 48 h with 2 µM bivalent 
aptamer siRNA transcripts targeting EEF2 mRNA (xPSM-B2-siEEF2; xPSM-B1_siEEF2) or displaying 
an EEF2 unrelated “nonsilencing” siRNA portion (xPSM-B2-non) Mean values of triplicate experiments 
are shown ±SEM; n:3; ANOVA: xPSM-B2non vs. xPSM-B2-siEEF2/ xPSM-B1-siEEF2 p<0,05. 
 
 
Inhibition of EEF2 by bacterial or plant derived toxins is known to selectively induce 
apoptosis via the intrinsic pathway that is accompanied by the upregulation of various 
apoptosis related caspases. In order to show that the observed toxicities could be 
addressed to the previous induction of apoptosis a colorimetric caspase 3/7 apoptosis 
assay (Promega) was performed (2.2.5.7). LNCaP cells were incubated with 2 µM 
aptamer siRNA transcripts for 48 h and subsequently the level of activated caspase 3 
and caspase 7 was monitored. Increased levels of these prominent caspases reflected the 
triggering of the apoptotic pathway. The results were normalized to untreated cells 
(representing 0% apoptosis). 
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Fig. 3.25: Caspase 3/7 apoptosis assay (2.2.5.7)of LNCaP cells (2.2.1) incubated with 2 µM of various 
aptamer siRNA transcripts for 48h. Caspase 3/7 levels were normalized to untreated cells (0% apoptosis). 
The known apoptosis inducer Zeocin was used as positive control.  
 
The bar diagram in Fig. 3.25 shows that the bivalent xPSM-B1-siEEF2 and xPSM-B2-
siEEF2 induced apoptosis in PSMA expressing LNCaP cells but not the nonsilencing 
xPSM-B2-non. These results provided strong evidence that the cytotoxic effects 
induced by xPSM-B1-siEEF2 and xPSM-B2-siEEF2 were related to the siRNA 
mediated EEF2 loss of function phenotype. 
The siRNA sequence specificity was further corroborated by quantitative RT-PCR 
analysis of EEF2 mRNA expression after treatment of LNCaP cells with 250 nM 
aptamer-siRNA targeting EEF2 for 24 h. The results obtained are shown in Fig. 3.26. 
Both bivalent transcripts significantly reduced EEF2 mRNA expression (xPSM-B1-
siEEF2: 38,9 ± 14,9%; xPSM-B2-siEEF2: 34,5 ±5,5%). Statistical analysis were 
performed by the one way ANOVA test resulting in p values p<0,05 indicating that the 
values obtained were statistically significant. 
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Fig. 3.26: Quantitative RT-PCR analysis of EEF2 mRNA expression (2.2.3.6). LNCaP cells (2.2.1) were 
treated with bivalent aptamer siRNA transcripts in the absence of transfection reagent at a concentration 
of 250 nM for 24 h. Subsequently cells were harvested and analyzed. Mean values are shown; error bars 
represent  (n:2; ± SEM). 
 
In conclusion all these results obtained showed that xPSM-B1-siEEF2 and xPSM-B2-
siEEF2 were efficiently taken up by PSMA expressing LNCaP cells. After being 
internalized these transcripts induced the siRNA mediated sequence specific 
degradation of target mRNA which finally led to the induction of cell death.  
 
3.2.10 Interferon β detection assay 
A major safety concern for the use of siRNA-based drugs is the induction of non-
specific inflammatory responses and subsequent cellular cytotoxicity. Especially long 
double stranded RNAs (> 30 bp) are prone to elicit strong interferon β responses as a 
cellular viral defence mechanism. The bivalent transcripts presented here did not 
comprise double stranded RNA stretches that were longer than 30 bp however due to 
the overall length of 173 or 234 nt respectively the induction of interferon β production 
had to be taken into account. 
For monitoring of interferon β response LNCaP and PC-3 cells were incubated with 
aptamer siRNA transcripts (1 µM) for 48 h before the secretion of interferon β into the 
cell culture supernatant was analyzed. Detection of interferon β was accomplished by 
using a commercially available sandwich interferon β ELISA kit (PBL) consisting of 
two interferon β specific monoclonal antibodies. The results obtained were compared to 
serial dilutions of an interferon β positive control provided with the kit. The results are 
shown in (Fig. 3.27). 
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Fig. 3.27: Interferon β detection assay (2.2.5.5). LNCaP and PC-3 cells (2.2.1) were incubated for 48 h 
with 1 µM bivalent aptamer siRNA transcripts before the secretion of interferon β into the cell culture 
supernatant was analyzed using a commercially available sandwich interferon β ELISA kit (PBL). 
 
None of the added aptamer siRNA transcripts induced an interferon β level higher than 
background (compared to untreated cells) could be detected. This indicated that under 
the conditions applied the aptamer siRNA transcripts did not trigger a type I interferon β 
response. 
 
3.2.11 Quantitative cell viability assays  
Finally the cytotoxic effects observed for the bivalent transcripts were compared to the 
effects of monovalent xPSM-A3-siEEF2.  
Since the biological activity is described by the overall efficacy as well as by the 
concentration at which the half maximal response (EC50) is obtained we analyzed cell 
viability in a dose dependent manner. LNCaP cells were incubated for 48 h either with 
monovalent or bivalent aptamer-siRNAs at concentrations ranging form 0,016 µM to 2 
µM. The resulting dose response curves are shown in Fig. 3.28. 
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Fig. 3.28: XTT viability assay (2.2.3.8) of LNCaP cells (2.2.1) incubated for 48 h with mono and bivalent 
aptamer siRNA transcripts targeting EEF2. Transcripts were applied in concentrations ranging from  
2 µM to 0,016 µM. IC50 values obtained were: xPSM-siEEF2 > 0,8 µM; xPSM-B2-siEEF2 0.17 ± 0.04 
µM and xPSM-B1-siEEF2 0.39 ± 0.07 µM. Error bars represent ±SEM. 
 
Dose dependent increase in cytotoxicity was obtained for the monovalent xPSM-A3-
siEEF2. However even at the highest transcript concentration cell viability was reduced 
by 45% demonstrating only moderate efficacy. For comparison, at the same 
concentration the bivalent transcripts reduced cell viability up to 98% thus 
demonstrating a large increase in efficacy.  
Due to the moderate efficacy of xPSM-A3-siEEF2 the dose response curve could not be 
subjected to nonlinear curve fitting procedures so that the IC50 was estimated to be far 
higher than >0,8 µM. Compared to x-PSM-A3-siEEF2 both bivalent transcripts showed 
a dramatic increase in cytotoxic efficacy as well as in potency with IC50 values being 
more than 5 fold lower. In addition the IC50 of xPSM-B2-siEEF2 which comprises two 
siEEF2 moieties was approximately two fold lower compared to x-PSM-B1-siEEF2 
(B2: 0.17± 0.04 µM; B1:  0.39± 0.07). Statistical analysis of these data with an unpaired 
students t-test resulted in a p-value p<0,05 indicating that the difference was statistically 
significant.  
 
3.2.12 Modular annealing bivalent aptamer-siRNA transcripts  
At this stage an other route to the generation of bivalent aptamer siRNA transcripts will 
be presented. In order to separate the two aptamer moieties the siRNA sequence was 
used as a long double stranded and rigid “spacer” sequence. In addition this spacer 
sequence might also be used as a splint sequence which could noncovalently connect 
two anti PSMA aptamers comprising complementary overhangs. The so connected 
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aptamer siRNA constructs might also fold into the same secondary structure as xPSM-
B2-siEEF2 (Fig. 3.29). 
 
 
Fig. 3.29:  Schematic composition of a bivalent “splint” annealing anti PSMA aptamer  
 
Since both monomers of this molecule did not comprise any repetitive sequences it was  
possible to generate the template DNA by assembly PCR using two overlapping primers 
(Fig. 3.30). 
 
Fig. 3.30: Assembly and amplification PCR (2.2.4.3)(2.2.4.4) of both monomers DNA templates for the 
bivalent “splint” anti PSMA aptamer siRNA transcripts. lane 1: amplification PCR of monomer 1 with 
flanking primers; lane 2: assembly PCR of monomer 1; lane 2: amplification PCR of monomer 2; lane 4: 
assembly PCR of monomer 2; lane 5: negative control. 
 
Both RNA monomers for this “splint” aptamer siRNA transcript called called, xPSM-
B1-anneal could be produced in a standard in vitro transcription reaction.  The assembly 
of both monomers was performed PBS buffer. Equal amounts of each monomer were 
heated to 95 °C and slowly cooled to room temperature.  
The stability of the resulting complex was then assayed by loading the annealed 
monomers onto a denaturing  8% urea PAGE gel. The ethidium bromide stained gel is 
shown in (Fig. 3.31) 
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Fig. 3.31: Ethidium bromide stained denaturing 8% urea PAGE gel (2.2.2.3) of the annealed xPSM-B1-
anneal and its corresponding monomers. Lane 1: Monomer 1; Lane 2: Annealed monomers forming 
xPSM-B2-anneal; Lane 3: Monomer 2  
 
A band at the expected size of the dimer was detectable indicating that both monomers 
efficiently annealed to complementary RNA strands of the opposite monomer. This 
splint sequence was stable enough not to completely dissociate during denaturing gel 
electrophoresis. 
Subsequently the binding affinity of the annealed xPSM-B1-anneal was determined in a 
flow cytometric assay (Fig. 3.32).  
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Fig. 3.32: Flow cytometric analysis (2.2.5.1) of FITC labelled and annealed xPSM-B-anneal (2.2.4.11) on 
PSMA expressing prostate carcinoma cells (2.2.1). Concentrations of FITC labelled annealed aptamer 
were in the range of 0,01 nM to 400 nM. The observed functional KD was approximately 150 nM.  
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Binding affinity was proved and the functional KD was determined to be in the same 
range as that observed for the other bivalent aptamer siRNA transcripts characterized 
previously.  
Gene silencing experiments which will be performed in the near future will reveal the 
potential of these kind of aptamer siRNA transcripts for the cell surface receptor 
specific delivery of functional siRNAs.  
 
3.2.13 Summary 
The presented results demonstrate that it was possible to design bivalent aptamer siRNA 
transcripts that comprised enhanced binding affinity and were taken up more efficiently 
by PSMA expressing LNCaP cells than their monovalent counterpart. It was proved that 
these transcripts were substrates for recombinant DICER. In accordance to the results 
obtained for siEEF2 the bivalent aptamer siRNA transcripts efficiently induced cell 
death only in PSMA expressing cells. These effects were further addressed to EEF2 
mRNA degradation by qPCR analysis. In comparison to the monovalent aptamer 
siRNA transcript the bivalent molecules showed significantly higher toxicities therefore 
demonstrating their potential for the cell surface receptor specific delivery of functional 
siRNAs.  
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3.3 Evaluation of siRNA-antibody conjugation strategies 
In the second approach functional siRNAs were selectively delivered into the target 
cells by covalent antibody-siRNA conjugates. The model antibodies of choice for these 
experiments were the anti CD30 specific mouse monoclonal IgG antibody Ki-4 (Ki-4 
IgG) and the corresponding recombinant single chain Fv antibody, Ki-4-svFv. Several 
conjugation strategies were tested for their applicability in the production of covalent 
siRNA-antibody conjugates. 
 
3.3.1 Conjugation via reductive amination 
Conjugation of biomolecues via reductive amination is a common strategy e.g. for the 
crosslinking of horseradish peroxidase to various detection antibodies. This two step 
procedure involves the periodate oxidation of vicinal diols present in glycosidic 
structures and subsequent formation of a “Schiff base” with a protein amino group that 
is further reduced by sodiumcyanogenborohydride. The 3’ ribose unit of the RNA can 
be oxidized by sodium metaperiodate resulting in reactive aldehyde groups  
Fig. 3.33) 
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Fig. 3.33:  Conjugation scheme of periodate oxidized RNA to protein amino groups.  
 
As a first test reaction the RNA was periodate oxidized and subsequently labelled with a 
carbonyl reactive fluoresceine derivative (Fluorescein-5-thiosemicarbazide) (Fig.3.34).  
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Fig.3.34: Analytical 8% urea PAGE gel (2.2.2.3) of periodate oxidized and subsequently fluoresceine 
thiosemicarbazide labelled RNA (2.2.6.3). A UV light picture without ethidium bromide staining lane 1: 
untreated RNA and lane 2: FITC labelled RNA. B UV light picture of corresponding ethidium bromide 
stained gel.    
 
Efficient labelling could be proved which showed that the oxidation reaction was 
successful. As a next step periodate oxidized RNA was conjugated to BSA as a model 
protein. Buffer conditions and reaction times and temperatures were optimized but no 
RNA protein conjugate could be detected in any of the conditions applied (pH: range 
from 7,4 to 10; reaction time from 1h to 48 h, RT to 40 °C reaction) (data not shown).  
 
3.3.2 Conjugation via N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide 
(EDC) activation coupling chemistry 
Next coupling was tried via the EDC activation of the 5’ mono-phosphate group .  
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Fig. 3.35: Scheme of EDC activation of a monophosphate group followed by the reaction with protein 
NH2 groups.  
 
Therefore the RNA was labelled with a guanosine-monophosphate initiator nucleotide 
during in vitro transcription reaction. In a first step of the reaction the RNA was 
activated with EDC and imidazole for 15 min at room temperature followed by the 
addition of BSA as a model protein.  
The resulting reaction mixture was analyzed by analytical urea PAGE gel 
electrophoresis and by SDS gelelectrophoresis (Fig.3.36). 
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Fig.3.36: Analytical gelelectrophoresis of RNA protein conjugation reaction. Guanosine-monophosphate 
labelled RNA was activated with EDC/Imidazole and subsequently reacted with BSA (2.2.6.1). A: 
Ethidium bromide stained 8% urea PAGE gel. Lane 1: free RNA; Lane 2: Conjugation reaction. B: 
Coomassie brilliant blue stained 12% SDS gel (2.2.2.2). Lane 3: Conjugation reaction Lane 4: free BSA. 
 
A shifted band RNA band could be detected in the urea PAGE gel and a shifted protein 
band could be detected in the corresponding SDS gel. This indicated that in principal it 
was possible to generate protein RNA conjugates by this method even though the yield 
of conjugated protein was low. However attempts to transfer this protocol to the 
conjugation of Ki-4 single chain or Ki-4 IgG failed (data not shown). 
 
3.3.3 Conjugation via reactive heterobifunctional linkers 
At this point all strategies to generate protein-siRNA conjugates that were based on the 
intrinsic reactivity of unmodified RNA either on the 3’ end or at the 5’ end failed. 
Therefore synthetic siRNAs were purchased comprising either a reactive amino group at 
the 3’ end of the siRNA sense strand or a 5’ thiol group also located at the siRNA sense 
strand.  
Three heterobifunctional linkers were used for these conjugation reactions, namely 2-
Iminothiolane (Sigma), N -Succinimidyl 3-(2-pyridyldithio)-propionate, SPDP (Pierce) 
and Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate, SMCC (Pierce) 
Fig. 3.37). 
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Fig. 3.37: Chemical structures of heterobifunctional linkers used.  
 
SPDP and SMCC both comprised an amino reactive NHS ester functionality and a thiol 
reactive portion which could be used for the conjugation of thiol containing 
biomolecules. For crosslinking purposes thiol groups were introduced either into the 
antibody or the siRNA by the reaction of primary amino groups with 2-Iminothiolane. 
In Fig. 3.38 a scheme of the chemistry that was applied for the conjugation reactions is 
shown. The main difference between SPDP and SMCC is the thiol reactive portion. The 
maleimide group present in SMCC leads to the formation of a stable thioether bond that 
is not prone to reductive cleavage. The pyridyldisulfide group of SPDP reacts with free 
thiols to potentially reducible disulfide bridges. Therefore differences in biological 
activity of the resulting conjugates might be addressable to the linker used. 
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Fig. 3.38: Scheme of the reactions applied for antibody siRNA conjugation. A: In a first reaction the 
siRNA and antibody were activated B: Crosslinking was performed in a second reaction upon removap of 
excess of activation reagent. 
 
The first step for antibody siRNA conjugation was to examine whether the activation 
reaction (Fig. 3.38; A) worked for all components used. Since the direct mass 
spectroscopic analysis of these reactions was difficult the success was monitored 
indirectly in a second reaction.  
If the pyridyldisulfide group of SDPD is reduced the resulting thiol group can react with 
thiol reactive dyes. Therefore both proteins, Ki-4 scFv and Ki-4 IgG, were activated 
with SPDP or 2-Iminothiolane and subsequently treated with an excess of 5-
Iodoacetylfluoresceine (5-IAF) under reducing conditions for 1h at room temperature 
(Fig. 3.39). In addition in order to exclude the possibility that any observed Ki-4 IgG 
staining was due to the reaction of native disulfide bonds the 2-iminothiolane activated 
Ki-4 IgG was also reacted with 5-IAF under non-reducing conditions.   
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Fig. 3.39: Analytical SDS gel of Ki-4 scFv and Ki-4 IgG after activation (2.2.6.2) (2.2.6.4) and 5-IAF 
treatment (2.2.6.5). A: Coomassie stained gel M: Prestained protein Marker (NEB) Lane 1: Ki-4 single 
chain SPDP activated, Lane 2 Ki-4 cFv 2-Iminothiolane activated, Lane 3: Ki-4 IgG SPDP activated; 
Lane 4: Ki-4 2-Iminothiolane activated. B: UV-light picture of the same SDS gel. C: UV-light picture of 
a SDS gel of Ki-4 IgG activated with 2-Iminothiolane and labelled with I5-IAF under nonreducing 
conditions in order to exclude that staining results only from native SH groups.     
 
The reaction products were separated by SDS gelelectrophoresis. Fluorescent bands 
could be detected for all proteins used. Furthermore the labelling reaction performed 
under nonreducing conditions also showed a fluorescent band of the intact Ki-4 full 
length antibody thus indicating that additional thiol groups could be introduced into 
both model antibodies used in this study.  
The same activation chemistry was applied to the siRNAs. The native PAGE gel after 5-
IAF labelling is shown in (Fig. 3.40). 
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Fig. 3.40: Analytical nondenaturing 15%  PAGE gel (2.2.2.4) of synthetic siRNAs after SPDP (2.2.6.6) 
or 2-Iminothiolane (2.2.6.7) activation and subsequent labelling reaction with 5-IAF (2.2.6.8). A:UV-
light picture of labelled siRNAs. lane 1: 5’thiol modified siRNA, lane 2: 3’ amino modified siRNA SPDP 
activated; lane 3: 3’ amino modified siRNA 2-Iminothiolane activated. B: Ethidium bromide stain of the 
same gel. M: siRNA marker (NEB). 
 
The siRNAs were also labelled with 5-IAF after SPDP or 2-Iminothiolane activation 
since fluorescent bands were detectable under UV light. Furthermore the activation 
reactions applied seemed to work equally well since according to the band intensities no 
significant difference was observed.  
These results showed that in principal any combination of activation and crosslinking 
should work for all proteins. However the first crosslinking experiments were 
performed with combinations of SPDP and 2-Iminothiolane activation in order to 
reduce siRNA consumption.  
 
3.3.4 Conjugation of Ki-4 single chain variable fragment 
Initially the Ki-4 scFv was activated by reaction with SPDP and subsequently reacted 
with 2-Iminothiolane activated siRNA. However after the final crosslinking step no 
protein could be recovered under any reaction conditions applied (data not shown). In 
order to identify at which step of the procedure the protein was lost several samples 
were analyzed at each step (Fig. 3.41).  
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Fig. 3.41: Analytical 12 % SDS gel (2.2.2.2) of Ki-4 scFv activated with SPDP (2.2.6.2). Lane 1: input of 
Ki-4 scFv into the labelling reaction; lane 2: Ki-4 scFv after 1 h incubation with SPDP in PBS; lane 3: Ki-
4 scFv after purification using sephadex G25 spin columns (Amersham). No protein can be recovered 
after gel filtration. 
 
After one hour of incubation with SPDP significant amounts of Ki-4 scFv were lost and 
no protein could be recovered after Sephadex G25 spin column purification (2.2.6.2). 
Various reaction conditions as well as purification methods were tested but it was not 
possible to increase the protein recovery to an acceptable level (data not shown). Since 
it was absolutely necessary to remove the excess of SPDP prior to crosslinking this 
strategy was not suitable for the generation of siRNAKi-4 scFv conjugates. 
If Ki-4 scFv was activated by 2-Iminothiolane the protein recovery after Sephadex G25 
spin column purification was significantly better (2.2.6.4q). Unfortunately no Ki-4 
scFv-RNA conjugates could be detected after the subsequent crosslinking reaction. An 
example of an analytical SDS gel after crosslinking reactions is shown  
 
 
Fig. 3.42: Analytical 12% SDS gel (2.2.2.2) of a Ki-4 scFv siRNA conjugation reaction (2.2.6.9). Lane 1: 
Ki-4 scFv after 2-Iminothiolane activation and subsequent sephadex G25 spin column purification. Lane 
2: subsequent conjugation reaction with SPDP activated siRNA. A very faint shifted band was visible 
however it was not stained with ethidium bromide indicating that no siRNA was conjugated to the Ki-4 
scFv antibody. 
 
86 Results 
Since it was not possible to use this strategy for the covalent attachment of siRNAs to 
this antibody fragment no further experiments were performed in this direction.  
 
3.3.5 Conjugation of Ki-4 mouse monoclonal antibody 
The majority of reports found in the literature dealing with the targeted delivery of 
chemically conjugated small molecule drugs, peptides or proteins use IgG antibodies as 
cell surface receptor specific ligands. Further more detailed protocols have been 
developed for the applications of heterobifunctional linkers such as SMCC or SPDP for 
the crosslinking of various biomolecules to full length IgG antibodies.  
Starting from these protocols currently available, crosslinking reactions for the covalent 
attachment of siRNAs to the Ki-4 IgG were developed. The most important parameter 
in this context is the optimization of the crosslinker/protein ratio because a too high 
excess of crosslinking agent might cause deleterious effects on protein activity. 
Here, reaction conditions were optimized for the activation of the Ki-4 IgG with SPDP 
or SMCC and 2-Iminothiolane. According to the activation chemistry used for the Ki-4 
IgG the siRNA was activated with SPDP, SMCC or 2-Iminothiolane. The ratio of 
siRNA to Ki-4 antibody was always kept constant at 10:1. Since no adverse effects for 
the siRNA had to be expected upon reaction with the crosslinking agent always a very 
large molecular excess was used (>100 fold).  
The analytical nondenaturing 5% PAGE gel in Fig. 3.43 shows the best results obtained 
for the activation of the Ki-4 IgG with 2-Iminothiolane. A 100 fold molecular excess of 
2-Iminothiolane was applied.  
 
 
Fig. 3.43: Analytical nondenaturing 5% PAGE gel (2.2.2.4) of Ki-4 IgG activated with a 100 fold 
molecular excess 2-Iminothiolane (2.2.6.2)(2.2.6.9). A: ethidium bromide stained gel, Lane 1: untreated 
Ki-4 IgG; Lane 2: siRNA activated with SPDP; Lane 3: siRNA activated with SMCC. B: corresponding 
Coomassie stained gel.  
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Due to the negative charge provided by the siRNA covalent antibody-siRNA conjugates 
migrate faster in a nondenaturing PAGE gel. Successful covalent conjugation could be 
proved since protein bands were detectable that were also stained by ethidium bromide. 
However even with a 100 fold molecular excess of 2-Iminothiolane still unconjugated 
antibody was detectable.. In addition crosslinking of SMCC activated siRNA seemed to 
be slightly more efficient compared to SPDP activated siRNA.  
Results for the activation of Ki-4 IgG with SPDP and SMCC are shown below (Fig. 
3.44).  
 
 
Fig. 3.44: 5% nondenaturing PAGE gel (2.2.2.4) of Ki-4 IgG activated with SPDP or SMCC (2.2.6.2) 
and reacted with a 10 fold molecular excess of 2-Iminothiolane activated siRNA (2.2.6.7)(2.2.6.9). A: 
Ethidium bromide stained gel; Lane 1: untreated Ki-4; Lane 2: Ki-4 IgG SPDP activated; Lane 3: Ki-4 
IgG SMCC activated. 
 
It turned out that a 30 fold molecular excess of SPDP or SMCC crosslinker resulted in a 
complete conjugation of the Ki-4 IgG. No unconjugated Ki-4 antibody could be 
detected after crosslinking reaction. In addition the samples activated with SMCC 
showed slightly better siRNA conjugation efficiencies. 
Next these conjugation reactions were further analyzed on a 15% nondenaturing PAGE 
gel in order to get an idea about the amount of siRNA that was conjugated to the 
antibody. The corresponding gel is shown in (Fig. 3.45). Based on the protein input of 
Ki-4 IgG equal amounts were loaded on the gel.  
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Fig. 3.45: 15 % native PAGE gel (2.2.2.4) of various Ki-4 siRNA conjugation reactions (2.2.7.1). Lane 1: 
equivalent amount of input siRNA; Lane 2: Ki-4 SPDP activated; Lane 3: Ki-4 SMCC activated; Lane 4: 
Ki-4 2-Iminothiolane activated + siRNA SPDP activated; Lane 4: Ki-4 2-Iminothiolane activated + 
siRNA SMCC activated.  
 
The resulting gel was stained with ethidium bromide and the image was analyzed by 
densiometry with the AIDA image analyzer software. Since no calibration curve was 
generated only a rough estimation of the amount of siRNA bound to the antibody was 
possible. According to the analysis for the SPDP and SMCC activated antibody 
approximately 30% of the total input siRNA was conjugated to the antibody which 
would mean that on average three siRNA molecules were attached to one antibody 
molecule. In case of the 2-Iminothiolane activated antibody approximately 10% of total 
input siRNA were shifted resulting in one siRNA molecule per antibody.  
Finally it is noteworthy that the protein recovery after crosslinking was rather low being 
in the range of 20 to 40% of the total protein input. The reason for that could not be 
identified yet and needs further research. 
 
3.3.6 Evaluation of binding affinity of antibody siRNA conjugates 
As a next step it had to be determined if the antibody functionality was retained during 
the conjugation procedure and if the generated Ki-4-siRNA conjugates would still 
comprise binding affinity to CD30 expressing L540 Hodgkin lymphoma cells. For the 
flow cytometric analysis approximately 1.5 µg of Ki-4-siRNA conjugates was used and 
compared to the shift obtained of 1.5 µg unconjugates Ki-4 IgG. The results of this 
experiment is shown in Fig. 3.46. 
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Fig. 3.46: Flow cytometric analysis of L540 cells incubated with 1.5 µg Ki-4-siRNA conjugates activated 
with SPDP  (blue) or activated with 2-Iminothiolane (pink) or 1.5 µg unconjugated Ki-4 IgG (green) 
(2.2.7.2).  
 
Binding activity of the unmodified Ki-4 antibody was higher compared to the Ki-4-
siRNA conjugates. But still a significant shift was observed for the Ki-4-siRNA 
conjugates on CD30 positive L540 cells. Therefore the conjugation chemistry applied 
was mild enough to retain the specific binding activity of the parent Ki-4 IgG.  
 
3.3.7 Evaluation of cytotoxic activity 
The major aim behind the generation of antibody-siRNA conjugates was the cell type 
selective delivery of functional siRNAs.  
Two different siRNAs were used for conjugation one “nonsilencing” siRNA targeting 
GFP and the already characterized EEF2 siRNA. In analogy to the experiments 
described above (3.2.11) for the delivery of aptamer-siRNA transcripts the final proof 
of the functionality of antibody-siRNA conjugates is the siRNA induced inhibition of 
protein biosynthesis and the subsequent induction of cell death.  
Cell viability was assayed 48h after Ki-4-siEEF2 conjugates were applied at an 
antibody concentration of 300 nM to CD30 expressing L540 cells. Additionally 
different crosslinking strategies were evaluated.  
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Fig. 3.47:  XTT-viability assay of CD30 receptor expressing L540 cells after a 48h incubation with Ki-4 
IgG crosslinked to siRNAs targeting EEF2 using different strategies (2.2.7.3). Either the siRNA was 
activated with 2-Iminothiolane (2.2.6.7) and reacted with SPDP or SMCC activated Ki-4 (2.2.6.2)(grey, 
white bars) or Ki-4 was activated with 2-Iminothiolane (2.2.6.4) and reacted with SPDP or SMCC 
activated siRNA (2.2.6.7)(crossed, black bars). For Ki-4-siGFP Ki-4 was SPDP activated and siGFP 2-
Iminothiolane. (average out of triplicates is shown ±SEM).   
 
For crosslinking either the antibody or the siRNA was activated with 2-Iminothiolane 
and reacted with SPDP or SMCC activated antibody or siRNA respectively. The 
difference between SPDP and SMCC was that the SPDP linkage resulted in a labile 
disulfide bond whereas with SMCC as crosslinking agent a rather stable thioether bond 
was formed. Astonishingly the overall effects of all Ki-4-siEEF2 conjugates were more 
or less equal. As shown in Fig. 3.47 all conjugates targeting EEF2 showed siRNA 
sequence specific toxic effects. Approximately 60 % of treated L540 cells was 
eliminated whereas no effects could be observed if the Ki-4 IgG was conjugated to 
siRNAs targeting GFP.  
These results demonstrate that it was possible to deliver covalently conjugated  siRNAs 
targeting EEF2 to CD30 expressing L540 cells by the use of the binding specificity of  
of Ki-4 IgG. 
 
3.3.8 Summary 
Protocols for the efficient covalent conjugation of synthetic siRNAs to full length IgG 
antibodies could be established. It was shown that the model antibody retained its 
binding specificity after being conjugated to siRNAs. In addition it could be shown that 
the antibody siRNA conjugate Ki-4-siEEF2 siRNA-sequence specifically induced cell 
death in CD30 positive L540 cells.  
 
  
4 Discussion 
4.1 siRNA mediated knock down of eukaryotic elongation 
factor 2 
Until now the most successful strategies against cancer have been the destructive ones.  
On the cellular level this implies efficient elimination of neoplastic cells. In traditional 
cancer chemotherapy this has been achieved with DNA or microtubule damaging agents 
like cis-platin or paclitaxel (119-121). Unfortunately the efficacy of such 
chemotherapeutic agents is mainly limited by the high overall cytotoxicity comprised by 
the drug itself. In recent years several small molecule based drugs have been developed 
that specifically target cancer associated proteins which leads to vastly reduced toxic 
side effects (122).  However a serious problem common to all small molecule based 
therapies is the ability of tumour cells to acquire resistance to various 
chemotherapeutics a phenomenon called multidrug resistance (40). Therefore new 
therapeutic approaches for the improvement of cancer therapy are still needed. 
Since every cell contains the RNAi machinery and in principal any protein-encoding 
gene can be targeted siRNAs offer great potential both for the discovery of new cancer 
associated target genes as well as for therapeutic applications (123-126). As a result of 
the largely improved technologies of high throughput gene expression profiling of 
cancer cells a wealth of information about new promising target genes that are 
dysregulated in many cancers is available (25). 
In this respect a prerequisite for the successful application of RNAi-based cancer 
therapy is the identification of potent siRNA sequences that selectively silence genes 
crucial for cell survival. However, since cancer cell progression is a multistep process in 
which a normal cell iterative acquires mutations that finally lead to relentless growth it 
is difficult to pinpoint key genes whose blockage would irreversibly lead to self 
destruction of cancer cells (127) (128).  
The most studies published in the literature so far have focused on the siRNA mediated 
knock-down of over expressed oncogenes of the c-myc or ras/ raf pathway (129,130). 
Albeit it could be demonstrated that the inhibition of these oncogenes significantly 
slowed down tumour growth it was not possible to efficiently eliminate cancerous cells. 
Another very promising class of proteins are anti-apoptotic proteins or apoptosis 
inhibitors like Bcl-2, FLIP, xIAP and survivin that mediate the acquired resistance of 
tumour cells towards apoptosis. However siRNA induced silencing of these genes only 
sensitized cancer cells to chemotherapeutic agents rather than inducing apoptosis 
directly. 
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One major aim of the present study therefore was to identify a target protein whose 
siRNA-induced knock down would efficiently trigger the apoptotic pathway without 
further exogenous stimuli.  
The target protein used for this study was eukaryotic elongation factor 2 (EEF2), a 
central component of the translational machinery. Inhibition of EEF2 by bacterial or 
plant derived toxins leads to the arrest of protein biosynthesis and subsequent efficient 
induction of apoptosis. In analogy it was expected that the siRNA mediated depletion of 
EEF2 mRNA would slow down protein biosynthesis and finally induce cell death. Up to 
now no data was available about the effects of siRNA mediated gene silencing of 
proteins that are involved in or regulate protein biosynthesis.  
In the present study it was possible to identify siRNA sequences that efficiently reduced 
EEF2 mRNA expression by up to 80% with an IC50 value in the range of 20 to 70 nM 
(Fig. 3.5). Currently the most potent siRNAs available display gene silencing potency in 
the sub- to low nanomolar range. From this point of view siEEF2 comprises only 
modest gene silencing activity. mRNA secondary structure analysis might result in 
information about the accessibility of the siRNA target sequences and could be used for 
siRNA sequence optimization (123,131). 
On the other hand it has to be taken into account that efficient silencing of EEF2 is 
accompanied by the inhibition of translation which in turn alters the expression as well 
as the mRNA levels of reference genes. A decrease in reference gene mRNA expression 
will lead to the underestimation of knock down efficiency because the ratio of target 
mRNA to reference mRNA rises. This might be especially important if the mRNA half 
life of the reference gene is significantly shorter compared to the half live of the gene of 
interest as it is the case for GAPDH and EEF2 (132,133). If this is considered the IC50 
values reported for siEEF2 might be overestimated. Therefore, qPCR analysis at 
different time points and with different reference genes might result in a more detailed 
characterization of the siRNAs targeting EEF2.  
For the present study however these experiments were omitted mainly because the most 
important question which had to be addressed regarding the characterization of siEEF2 
was whether the siRNA mediated silencing of EEF2 would induce cell death in cancer 
derived cell lines.  
Cell viability assays showed that transfection of siEEF2 duplexes specifically induced 
cell death in several cancer derived cell lines (Fig. 3.7). These effects were achieved 
after a single administration of siEEF2 and without the application of further apoptosis 
inducing agent.  
The IC50 values obtained were approx. two to three fold higher as those observed for 
EEF2 mRNA knock down being in the range of 80 to 150 nM, depending on the cell 
lines. The most likely explanation for this observation is that only a high EEF2 mRNA 
knock down finally results in cell death. Obviously a 50% reduction of EEF2 mRNA (at 
IC50 siEEF2 concentration) was not high enough to induce a loss of function phenotype 
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that led to cell death. The catalytic activity of EEF2 underlies tight post-translational 
regulation by phosphorylation mediated by a specific calmodulin dependent kinase 
(elongation factor 2 kinase; EEF2-k) and can be significantly reduced for instance as a 
result of low nutrient concentrations (63). Therefore it appears likely that the siRNA 
mediated induction of cell death can be attributed to a certain EEF2 protein knock down 
threshold which has to be achieved. A study about siRNA kinetics presented by Bartlett 
et al. demonstrated that depending on the target mRNA turnover and protein half life a 
higher degree of gene silencing over a longer period of time can be achieved by 
adjusting the dosage regimen (134). According to the mathematical model for the 
prediction of siRNA effects over time presented in this study the cytotoxic effects of 
siEEF2 might be enhanced by changing from a single administration strategy to 
repeated pulses of lower doses of siEEF2.  
At this stage the overall cytotoxic activity of siEEF2 will be correlated with some 
general facts about of eukaryotic elongation factor 2. Elongation factor 2 catalyzes the 
translocation of the aminoacyl t-RNA from the A site to the P site of the ribosome 
during the peptide chain elongation step of the protein biosynthesis. Gill et al. estimated 
the number of EEF2 molecules per ribosome to be in the range of 1 to 1.5 which means 
that a eukaryotic cell according to the number of ribosomes roughly contains several 
million copies of EEF2 (Fig. 4.1). 
 
 
Fig. 4.1: Electron micrograph of a thin section of the cytoplasm of a eukaryotic cell. Ribosomes are 
indicated by the black dots (arrows). Picture out of ref. (135). 
For comparison the copy number of c-myc which represents a protooncogene 
overexpressed in many cancers was estimated to be 29000 transcripts in lung cancer 
fibroblasts. From this point of view, regarding the high expression level of EEF2, the 
potency of siEEF2 seems to be very high. In this special case the siRNA activity might 
also be limited by the overall catalytic turnover of the endogenous RNAi machinery 
(136).   
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The comparison of the cytotoxic potential of siEEF2 to siRNAs targeting other common 
anti-apoptotic proteins is difficult because studies addressing siRNA potencies in a dose 
dependent manner are rare. However siRNA concentrations between 10 and 150 nM 
were used for the silencing of antiapoptotic proteins which indicates that the overall 
cytotoxic activity of siEEF2 is in a reasonable range (137-140). 
In conclusion, the siRNA based targeting of EEF2 represents a new approach for the 
siRNA mediated induction of apoptosis. The general advantage to target such an 
ubiquitously expressed protein is that in principal every neoplastic cell will be 
eliminated independent from its genetic background or phenotype.  
siRNAs targeting EEF2 are very well suited for cell type specific drug delivery 
applications because this will eliminate the risk of potential side effects if the siRNA is 
taken up by nontargeted cells or tissues.  
 
4.2 Cell surface receptor mediated siRNA delivery  
One of the major challenges for the in vivo application of siRNA-based drugs is the 
development of effective strategies for cell type-specific siRNA delivery (141). 
In this respect RNA aptamers are very well suited for the targeted delivery of 
therapeutically active molecules since they comprise affinities and specificities that are 
in the range of antibodies (59,142).  
Most published studies dealing with aptamer mediated drug delivery applied the anti 
PSMA aptamer xPSM-A10 (61,62,143,144). First of all because this aptamer 
specifically binds to the very promising tumour marker PSMA that is predominantly 
expressed on prostate cancer cells and second of all this aptamer consists of pyrimidine 
nucleotides that comprise a 2’fluoro-ribose modification which renders the aptamer far 
more stable towards nuclease degradation (60).  
Here the anti PSMA aptamer was used as the targeting ligand for the cell surface 
receptor specific delivery of functional siRNAs.  
The basic prove-of-concept experiment was achieved by Inga Neef (Fraunhofer IME, 
Aachen). She fused siRNAs targeting EEF2 to the 3’ end of the anti PSMA aptamer 
xPSM-A10-3 as a shRNA. It could be demonstrated that this aptamer siRNA transcript 
was specifically taken up by PSMA expressing LNCaP cells and led to siRNA sequence 
specific degradation of target mRNA which finally resulted in the induction of cell 
death.  
However the observed toxicities were only moderate with an overall efficacy of only 
45% cytotoxicity and an IC50 value of >0,8 µM. Most likely these results could be 
explained by the poor cellular uptake of the monovalent aptamer siRNA transcript (Fig. 
3.28).  
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Therefore, it is assumed that the internalization rate would be improved by increasing 
the valency of the anti PSMA aptamer. Thus, the major aim of the present study was the 
design and characterization of bivalent aptamer siRNA transcripts.  
Since it was shown by Liu et al. that the internalization rate of PSMA could be 
enhanced upon antibody administration it was aimed to generate bivalent aptamer 
siRNA transcripts that displayed “antibody like” binding characteristics (96).  
Two bivalent aptamer siRNA transcripts were rationally designed according to mfold 
webserver based secondary structure prediction. The siRNA was inserted in between the 
two aptamer moieties and served as a “spacer” sequence in order to provide a 
sufficiently long and rigid dsRNA linker that allowed independent folding of the two 
aptamer sequences. However this was not the only reason for the insertion of the siRNA 
portion in between the two aptamer moieties. An RNA helix of only eight base pairs 
would have been long enough to efficiently separate the two aptamer sequences. The 
second reason was to separate the two binding moieties by a spacer that would be in the 
same range of the distance between two antigen binding sites of an IgG antibody. A 
regular Fab fragment has a length of roughly 60 nm which means that the biggest 
distance between antigen binding sites can be 120 nm. Additionaly the hinge region of 
the antibody further increases its flexibility. With the dsRNA helix of 22 bp of length 
the molecular dimensions of the aptamer are close to that of an IgG antibody (145). 
RNA helixes adopt A-DNA like structures having 10 bases per turn and spanning 25 
nm. The siRNA helix therefore measures 50 nm and each helix of the aptamer stem 
loop adds another 25 nm. In total the maximum distance between two aptamer binding 
sites is approximately 100 nm. The flexibility is provided by single stranded RNA 
stretches that were added immediately adjacent to each aptamer moiety. Therfore these 
bivalent aptamer siRNA transcripts potentially comprise antibody like characteristics 
(Fig. 3.9 and Fig. 3.10). 
The affinity to PSMA expressing LNCaP cells observed for the monovalent xPSM-A3-
siEEF2 (kD: 0,81 µM) was in well accordance to the published data for the anti PSMA 
aptamer (146). In addition, it was shown that both bivalent aptamer siRNA transcripts 
showed a two fold higher binding affinity to LNCaP cells. This clearly proved that both 
aptamer moieties of the bivalent aptamer siRNA transcripts fold into their active 
conformation since the potential explanation for the increased affinity are positive 
avidity effects (Fig. 3.16).  
In order to monitor the internalization efficiency of these transcripts a new 
internalization assay was established. Until now no internalization assay was published 
which could be used for monitoring time dependent internalization of a cell surface 
bound aptamer. Even though radioactive internalization assays were reported to be very 
sensitive and thus well suited for these kinds of applications it was not possible to 
monitor aptamer internalization with this method mainly because the sample to sample 
variation was too high. The main reason for that were problems in handling LNCaP 
cells. Since LNCaP cells are growing in more or less loosely attached colonies it 
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appeared to be very difficult to wash them in 24 well plates without significant loss due 
to detached cells. Furthermore a flow cytometric internalization assay failed in which 
the cell surface bound fluorescence should have been quenched by the addition of 
trypan blue staining solution (data not shown). Here extracellular fluorescence 
quenching was not efficient enough. Finally it was possible to remove cell surface 
bound aptamers via Proteinase K treatment and thus specifically detect the amount of 
internalized aptamer siRNA transcript (Fig. 3.19). In several publications Proteinase K 
treatment was applied to remove either small molecule ligands or protein based ligands 
from the cell surface by proteolytic degradation of cell surface target proteins (147). 
This was also observed here and in addition the Proteinase K treatment was well 
tolerated by LNCaP cells (Fig. 3.18).  
Finally, after having established an accurate and reliable flow cyotmetric internalization 
assay it was proven that the bivalent aptamer siRNA transcripts were taken up far more 
efficiently compared to the monovalent aptamer siRNA transcripts (Fig. 3.21).  
Some theoretical considerations will show that the data obtained from these assays are 
in accordance with the current literature. As already mentioned it was published by Liu 
et al. that upon antibody binding the internalization of PSMA could be enhanced. In this 
study they reported that PSMA is constitutively internalized with 15% of the total 
PSMA content being present in intracellular compartments. Upon administration of an 
anti-PSMA monoclonal antibody the relative amount of internalized PSMA increased 
within 1h from 15% to 60% and remained more or less constant for another 60 min. For 
the internalization experiments performed here LNcaP cells were incubated with 400 
nM FITC labeled aptamer siRNA transcripts which roughly represented the kD 
concentration. This means that approximately 50% of all aptamer binding sites were 
occupied during the assay. After 1h of incubation a relative internalization of initially 
bound aptamer siRNA transcripts of 8% in case of monovalent xPSM-A3-siEEF2 and 
32% of bivalent xPSM-B2-siEEF2 was observed. Given that there is only one aptamer 
binding site per PSMA molecule this would mean that 8% of 50% occupied PSMA 
molecules (16% of total PSMA) internalized after administration of the monovalent 
aptamer. This means that the monovalent aptamer is taken up with a rate equal to the 
constitutive uptake of PSMA. For the bivalent transcript however 32% of the 50% 
occupied PSMA molecules were found to be internalized which indicates that the 
bivalent transcripts induce an increase in total PSMA uptake similar to that obtained by 
the anti PSMA antibody. Even though the data correlate well with the findings of Liu et 
al. the final prove of these results can only be obtained if the total amount of aptamer 
induced internalized PSMA would be determined.  
Subsequently in vitro DICER cleavage assays showed that both bivalent transcripts 
were efficiently processed by DICER into small RNA fragments of typical size of a 
siRNA (21 to 23 nt). Incubation of the aptamer xPSM-A10-3 with the DICER enzyme 
also resulted in a distinct RNA band that additionally could be found in every other 
reaction. This observation is somewhat contradictory to the results presented by 
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McNamara et al. who also performed in vitro DICER assays with this anti PSMA 
aptamer but did not see any degradation products of the aptamer and thus concluded 
that it did not serve as DICER substrate (146). But since it was demonstrated already 
that the monovalent aptamer did not cause any unspecific side effects no more detailed 
analysis was performed in order to find a reason for this result.  
Even though two reports about the aptamer mediated delivery of short interfering RNAs 
demonstrated that application of aptamer siRNA chimeras in LNCaP cells did not 
induce any unspecific interferon β production the same assay was repeated for the 
bivalent transcripts xPSM-B1-siEEF2 and xPSM-B2-siEEF2. In accordance to the 
publication of Chu et al. and McNamara et al. no unspecific interferon β production was 
detectable. At this point it is noteworthy that the bivalent transcripts were approx. twice 
as long as the afore mentioned aptamer siRNA chimeras applied by McNamara et al. 
indicating that obviously the induction of  unspecific inflammatory effects is not strictly 
ruled by the length of the applied RNA molecule. This experiment further demonstrated 
that potential cytotoxic effects of the transcripts are caused by the siRNA mediated gene 
silencing. 
Taken together, these results indicate that the bivalent aptamer siRNA transcripts 
displayed a much higher efficacy and a significantly increased potency compared to the 
monovalent xPSM-A3-siEEF2. Additionally the observed siRNA mediated induction of 
cell death was highly restricted to PSMA expressing LNCaP cells. The siRNA sequence 
specificity of the cytotoxic effects observed could be proven by the corresponding “non 
silencing” bivalent aptamer siRNA transcript.  
The data presented here lead to the conclusion that the enhanced biological activity can 
be addressed to improved cellular uptake which potentially results in a higher 
intracellular concentration of functional siRNAs. This might also explain why xPSM-
B2-siEEF2 comprising two siRNA moieties shows a lower IC50 value in the viability 
assays compared to xPSM-B1-siEEF2 containing only one single siRNA portion. This 
indicates that the siRNA payload of aptamer siRNA transcripts can enhance the overall 
biological potency.  
Since this is the first report about the generation of bivalent aptamer siRNA targeting 
agents the results are difficult to compare with the data presented in the literature so far. 
The aptamer-streptavidin-siRNA fusion molecules described by Ellington et al. 
basically are bivalent constructs due to the statistical occupation of the four biotin 
binding sites of streptavidin by biotinylated siRNAs and biotinylated aptamers. 
However comparative data of monovalent vs. bivalent constructs are lacking in this 
study. Besides that gene silencing effects were only demonstrated by the knock-down of 
the intermediate filament protein Lamin A/C a common house keeping gene oftentimes 
used as reference gene in siRNA experiments (87).  
The monovalent aptamer siRNA chimeras presented by McNamara et al. are similar to 
the monovalent constructs applied here. But unfortunately the apotosis inducing activity 
of their aptamer siRNA chimeras was not evaluated in a dose dependent manner. 
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However, the fact that they monitored cell viability after duplicate administration of 400 
nM of their chimeras and after 96 h of incubation might be a hint on moderate toxicities 
observed after a single administration.  
Since RNA aptamers are nonimmunogenic and nontoxic our approach of generating 
fully RNA based bivalent delivery agents may have the advantage of less side effects 
compared to protein based delivery agents. In addition the increased molecular weight 
and avidity of these bivalent transcripts might lead to better pharmacokinetic properties 
like circulatory half live or tumour penetration characteristics when administered 
systemically (49,148). Besides that the modular design of these bivalent and 
bifunctional aptamer siRNA transcripts might be transferable to other tumour cell 
surface specific aptamers. 
In this respect the presented bivalent annealing aptamers are of special interest because 
due to their smaller monomer size they might soon become amenable by solid phase 
RNA synthesis techniques. This would largely reduce the production costs and since no 
biological systems would be involved in the production process it might be easier to 
obtain FDA or EMEA approval for these kinds of molecules.   
In general cell type specific siRNA delivery is especially important for apoptosis 
inducing siRNAs because nonspecific uptake could also kill healthy cells. In this respect 
PSMA is a very promising target for cell specific drug delivery applications because it 
is predominantly expressed on prostate cancer cells and on the neovasculature of many 
other solid tumours (149). Only low level expression of PSMA has been detected in 
other tissues like kidney, colon and duodenum which does not diminish the therapeutic 
potential of PSMA for immunotherapy (61,95,150,151).  
In combination with the highly specific PSMA aptamer the siRNA targeting EEF2 
might be developed to universal apoptosis inducing agents for the selective elimination 
of PSMA expressing cells in various malignant diseases.  
Beyond the application of aptamer siRNA transcripts in cancer therapy the approach 
presented in this thesis further offers the possibility to serve as platform technology for 
the tissue selective in vivo delivery of functional siRNAs not only for therapy but also in 
order to address questions of basic research. siRNAs targeting regulatory proteins or 
even miRNAs could be incorporated into these targeting complexes and thus would 
open the way for organ specific transient phenotypic analysis.   
 
4.3 Antibody mediated siRNA delivery 
In a second approach cell surface receptor specific delivery of functional siRNAs was 
based on covalent siRNA antibody conjugates.  
In recent years several reports about antibody small molecule drug conjugates for the 
therapy of cancer were published (152). This indicated that antibodies are very well 
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suited for the cell type specific delivery of various biologically active molecules 
potentially also siRNAs.  
For the generation of covalent antibody siRNA conjugates two different antibody 
formats were applied. On the one hand it was tried to attach the siRNA to an anti CD30 
receptor specific single chain antibody fragment Ki-4 single chain and on the other hand 
a full length monoclonal IgG antibody (Ki-4). 
The immunotherapeutic potential of both targeting antibodies was well documented. 
Toxicity to CD30 expressing L540cy cells was shown first by a chemically crosslinked 
Ki-4 IgG-ricin A-chain immunotoxin indicating that Ki-4 IgG well tolerates various 
conjugation chemistries (107). Ki-4 scFv was shown to exhibit antigen specific toxicity 
as a recombinant expressed fusion protein Ki-4(scFv)-ETA’. 
In order to establish basic protocols for the production of RNA protein conjugates initial 
experiments were preformed with RNA derived of in vitro transcription reactions and 
BSA as a model protein. Using the standard EDC/Imidazole conjugation method RNA-
BSA conjugates were obtained in moderate to low yields (Fig. 3.35). Furthermore it 
was not possible to successfully transfer this protocol to the conjugation of other 
proteins than BSA. The most likely explanation for these findings is that the isoelectric 
point of BSA is far lower compared to Ki-4 IgG or Ki-4 scFv. Since the conjugation is 
performed at neutral pH possibly BSA comprises more nucleophilic primary amine 
groups. This means in conclusion that the reactivity of the activated 5’ phosphate group 
is not high enough to efficiently react with protein amino groups.  
Since all attempts to conjugate in vitro transcribed RNA to any of the targeting 
antibodies failed the conjugation strategy was changed. Synthetic siRNA molecules 
were purchased from Dharmacon that carried a reactive amino group at their 3’ end of 
the siRNA sense strand. In order to increase the nuclease resistance of these RNA oligos 
two phosphodiester bonds at each end of the RNA oligo were replaced by two 
phosphorothioate bonds and two 2’-O-methyl modified nucleotides were incorporated at 
the 3’ end. These modifications were chosen because it has been previously published 
that they were well tolerated without impairing the siRNA activity (78,153-155). 
Transfection experiments of these synthetic siRNAs targeting EEF2 showed that the 
cytotoxic potential was comparable to that observed by the unmodified siEEF2 siRNA 
(data not shown). If siRNAs are transfected via cationic lipofection reagents the siRNA 
is protected from serum RNAses by the lipid shell that surrounds the siRNA molecule 
therefore serum stability assays comparing the stability of unmodified and modified 
siEEF2 might reveal stability differences caused by these modifications.  
In this study, Ki-4 scFv was the protein of choice for conjugation experiments because 
it was aimed to create antibody-siRNA conjugates that were based on recombinant 
proteins. Unfortunately it turned out that it was not possible to generate Ki-4 scFv RNA 
conjugates. Even though the successful activation of Ki-4 scFv with SPDP and 2-
iminothiolane could be proved via a secondary FITC labelling reaction it was not 
possible to remove the excess of activation reagent prior to the RNA-crosslinking 
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reaction. For all reaction conditions applied and purification strategies pursued the final 
yield of repurified Ki-4 svFv was too low for a further RNA conjugation reaction. 
Perhaps the activation of primary amino groups led to the aggregation of the antibody 
which finally was the reason why the protein recovery after various size exclusion 
methods was so low. According to Dr. Michael Huhn (Fraunhofer IME, Aachen) 
(personal communication) these observations were in consistence with his own 
experiences with the purification of Ki-4 scFv antibody. Thereby this antibody fragment 
was very sensitive to buffer exchange and prone to precipitate during purification. 
Further experiments in this direction using different single chain antibodies might reveal 
whether these results have to be addressed to the properties of Ki-4 scFv or to the 
conjugation protocol applied. However, in principal single chain antibodies can 
successfully be modified and crosslinked to other proteins via SPDP activation as 
demonstrated by Dewerchin et al.(156). 
By using the monoclonal Ki-4 IgG antibody it was possible to generate covalent siRNA 
antibody conjugates. After optimization of the reaction conditions applied it turned out 
that activation of the antibody with the heterobifunctional linker SPDP or SMCC 
respectively finally resulted in a higher yield of siRNA-conjugated antibody            
(Fig. 3.44). If the antibody was activated with 2-iminothiolane no complete siRNA 
labelling could be achieved since unconjugated antibody was still present after RNA 
crosslinking (Fig. 3.43). This result was rather astonishing since according to the 
literature the reactivity of 2-iminothiolane towards primary antibody amino groups 
should be equal or even higher compared to the NHS ester group which was used as 
amino reactive moiety in SPDP or SMCC (157,158).  
Quantification of the ratio of antibody bound siRNA and free siRNA after conjugation 
revealed that approx. three siRNA molecules were attached to one antibody molecule if 
activation was performed with SPDP or SMCC. The overall ratio of antibody to siRNA 
molecules of 2-iminothiolane activated IgG was approximately one to one even though 
it has to be considered that still unconjugated antibody was present in the solution. 
Since in these reactions the RNA was used in a 10 fold molecular excess already it 
might not be possible to achieve a higher siRNA payload. 
Finally it has to be mentioned that the overall antibody recovery after siRNA 
crosslinking and final purification was rather low being in the range of 20 to 40% of the 
total antibody input. Unfortunately the overall protein yields of antibody conjugation 
reactions are rarely published which makes it difficult to comment on this. The gel 
filtration matrices used for purification usually allow 90% of protein input to be 
recovered. If RNA is bound to the antibody potential electrostatic interactions of the 
RNA with the gel filtration matrix lead to higher retention.  
Flow cytometric analysis of Ki-4-siRNA binding to human Hodgkin-derived cells 
revealed that the binding activity of the Ki-4-siRNA conjugates was retained. Finally it 
was demonstrated that the Ki4-siEEF2 conjugates displayed cytotoxic activity on CD30 
expressing L540cy cells. A corresponding conjugate of the antibody to an EEF2 
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unrelated siRNA did not show any effects demonstrating the siRNA sequence specific 
effects.  
The observed cytotoxic activity was more or less equal no matter what kind of 
conjugation strategy was applied or what kind of linker was used. Future experiments in 
which the cytotoxic activity will be correlated to the dosage might reveal differences in 
potency. However, the fact that conjugates comprising a potentially labile linker were 
equally active compared to conjugates in which a stable thioether linkage is present 
shows that intracellular processing does not depend on linker stability. Until now no 
data is available about the application of antibody-siRNA conjugates for the cell type 
specific deliver of siRNAs. Several reports about the covalent conjugation of siRNAs to 
cell penetrating peptides (CPP) have been published but since the uptake of these 
conjugates is very different from the uptake via receptor mediated endocytosis a 
comparison is difficult (159).  
In conclusion the presented data can be considered as a first prove of concept indicating 
that in principal it is possible to a) covalently attach siRNAs to cell surface specific 
antibodies while retaining the binding activity and b) to achieve cell surface receptor 
specific uptake of the conjugates followed by the siRNA mediated suppression of target 
genes. These promising first results have to be further substantiated which will require 
more experiments in order to answer questions about the gene silencing activity, the cell 
surface specificity and the concentration dependency of the created Ki4-siEEF2 
conjugates. 
 
 
  
5 Outlook 
 
For the development of siRNA based drugs two aspects are of crucial importance. The 
identification of potent siRNA sequences that efficiently silence the expression of the 
disease causing or disease related protein and the efficient and safe delivery of 
functional siRNAs to specific organs, tissues or cell types.  
The siRNA targeting EEF2 represents a new siRNA that selectively induced cell death 
in various cancer derived cell lines independent from their genetic background or 
phenotype. More detailed analysis of the mechanism and kinetics of gene silencing of 
this siRNA might show that altered dosage regimen, like repeated administration of 
siRNA for instance will have beneficial effects for the cytotoxic activity. Furthermore 
comprehensive analysis of the siRNA targeting EEF2 and other apoptosis inducing 
siRNAs will provide valuable information about the efficacy of this siRNA. Since EEF2 
is expressed in every cancer cell the siRNA targeting EEF2 might be developed to a 
universally applicable siRNA sequence for the elimination of various different 
neoplastic cells. Therefore it is aimed to test the efficiency of this siRNA in 
combination with innovative delivery strategies in tumour mouse models in vivo. 
It was shown that aptamers are valuable cell surface specific ligands for the delivery of 
functional siRNAs and that increasing the valency of such lignands results in 
dramatically enhanced functional activity. In order to further increase the potency of 
these kind of molecules it is necessary to characterize the mechanism of action in more 
detail. Quantitative DICER cleavage assays for instance could help to design second 
generation bivalent aptamer-siRNAs that are processed more efficiently. In addition to 
that currently only very little is known about the exact uptake mechanism and 
intracellular processing of these aptamer-siRNAs. More information about the 
translocation step from the endosome to the cytosol of target cells might open the way 
to create aptamer-siRNA with improved translocation characteristics. 
Since the final goal is the development of efficient siRNA based cancer therapeutics the 
generated delivery agents have to be tested in animal models in vivo. It is anticipated to 
establish a disseminated prostate tumour mouse model in which the aptamer-siRNAs 
will be administered systemically. Therefore it would also be straightforward to test 
chemical modifications like cholesterol conjugation or PEGylation of these constructs 
to potentially improve their pharmacokinetic properties.  
In the present thesis it was also possible to demonstrate that functional siRNA delivery 
can be achieved with covalent antibody-siRNA conjugates. The covalent attachment of 
siRNAs to antibodies represents a very promising approach for siRNA delivery since 
many cell surface specific full length antibodies are available that can be used in this 
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experimental setting. Here as well more detailed analysis about the intracellular routing 
of antibody-siRNA conjugates will result in valuable information that could be used for 
the development of improved crosslinking agents in order to increase the siRNA 
efficiency. Finally these conjugates also have to be tested for the efficacy in tumour 
mouse models when administered systemically.  
In conclusion the strategies for the cell type specific delivery of functional siRNAs 
presented in this thesis offer the possibility to be developed as valuabe tools not only for 
the application in cancer therapy but also for basic research. The design principels for 
the bivalent aptamer-siRNAs as well as the conjugation chemistry that was applied for 
the generation of antibody-siRNA conjugates should be easily transferable to other cell 
surface specific aptamers or antibodies so that a board range of applications for the 
delivery of siRNAs can be anticipated.  
 
 
  
6 Summary  
RNA interference (RNAi) represents an evolutionary conserved mechanism for the 
posttranscriptional regulation of gene expression first discovered in plants and 
flatworms. The demonstration of RNA interference in mammalian cells in 2001 was the 
starting point for very intensive research in this field in order to harness this powerful 
endogenous gene silencing mechanism for human therapy. In higher eukaryotes 
posttranscriptional gene silencing is mediated by short interfering RNAs (siRNAs) that 
induce the sequence specific degradation of complementary mRNA. For cancer therapy 
siRNA-based drugs offer the potential to selectively eliminate neoplastic cells by the 
silencing of genes that are crucial for cell growth and viability. 
Unlike small molecule drugs siRNAs are not passively taken up by target cells. 
Therefore the efficient intracellular delivery of functional siRNAs is one of the biggest 
obstacles which have to be overcome for the widespread therapeutic application of 
RNA interference based drugs.  
The first aim of this thesis was to characterize the efficacy of siRNAs directed against 
eukaryotic elongation factor 2 (EEF2), a key component of the translational machinery. 
Efficient inhibition of EEF2 should result in the induction of apoptosis and cell death. 
It was possible to identify potent siRNA sequences that efficiently and sequence 
specifically mediated EEF2 gene silencing. Furthermore it was proven that the siRNA 
induced depletion of EEF2 mRNA efficiently induced cell death in various cancer 
derived cell lines. These data clearly demonstrate the high potential of siRNAs targeting 
EEF2 to be used as cytotoxic component for siRNA based cancer therapy. Thus, siEEF2 
represents a new contribution to the repertoire of apoptosis inducing siRNA sequences.   
The second aim of this thesis was the evaluation of two strategies for the ligand 
targeted, cell surface receptor specific delivery of functional siRNAs directed against 
EEF2. 
Here the affinity of an RNA-aptamer specifically binding to the prominent tumour 
marker PSMA that is overexpressed on the cell surface of prostate cancer cells was 
exploited for the cell surface specific delivery of Aptamer siRNAs. Previous studies 
have demonstrated that by the use of monovalent anti PSMA aptamer it was possible to 
deliver siRNAs to PSMA expressing LNCaP cells. However the overall activity 
observed in these experiments was only moderate. Therefore it was aimed to increase 
the therapeutic efficacy of the monovalent aptamer siRNA transcript. Since the 
internalization rate of PSMA can be increased upon binding of an anti-PSMA antibody 
it was predicted that the internalization of the aptamer siRNA transcripts and thus their 
efficiency could be enhanced by increasing their valency by rational design. Two anti 
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PSMA aptamers were assembled in a way that each binding sequence could 
independently fold into its active conformation.  
It was shown that the binding specificity of the bivalent aptamer siRNA transcripts was 
comparable to that of the monovalent transcript. The binding affinity of the bivalent 
aptamer siRNAs however was approximately two fold higher.  
In order to characterize the internalization characteristics of the aptamer siRNAs a new 
flow cytometric internalization assay was established which allowed to monitor the 
internalization in a quantitative and time resolved manner. 
The data obtained showed that bivalent transcripts were internalized up to four fold 
more efficiently compared to the monovalent xPSM-A3-siEEF2. After 60 min 
approximately 32% of initially bound bivalent transcripts were internalized wheras only 
8% of the of initially bound monovalent aptamer siRNAs were taken up by LNCaP 
cells.  
It could be proven that cytotoxic effects of the bivalent aptamer siRNA transcripts could 
be addressed to the siRNA mediated depletion of EEF2 mRNA and were restricted to 
PSMA expressing LNCaP cells. Besides that these effects were siRNA sequence 
specific.  
The bivalent transcripts exhibited a dramatic increase in cytotoxic efficacy and potency 
compared to their monovalent counterparts. These data lead to the conclusion that the 
enhanced biological activity could be addressed to the improved cellular uptake which 
leads to a higher intracellular concentration of functional siRNAs.  
The second approach for the cell surface receptor specific delivery of siRNAs involved 
the generation of covalently bound siRNA-antibody conjugates.  
Here synthetic siRNAs carrying a reactive amino group at the 3’end of the siRNA sense 
strand were efficiently conjugated to an anti CD30 specific full length antibody by the 
application of two different heterobifunctional linkers (SPDP/SMCC). Antibody-siRNA 
conjugates in which SPDP was used were linked over a potentially labile disulfide bond 
whereas SMCC conjugates were connected over a stable thioether bond. On average 
three siRNA molecules could be fused to one antibody. The conjugation chemistry 
applied did not affect the antibody binding characteristics.  
Finally it was demonstrated that the generated antibody-siRNA conjugates siRNA 
sequence specifically induced gene silencing and subsequent cell death in CD30 
expressing L540cy Hodgkin lymphoma cells. Until now this is the first report 
describing the specific gene silencing of covalent antibody-siRNA conjugates.  
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8 Appendix 
8.1 List of abbreviations 
5'-IAF  5’-Iodoacedamidofluoresceine 
Ab   antibody 
ABTS   2,2’-azino-di-[3-ethylbenzthiazoline sulfonate(6)] 
AC  acetate 
ACN   acetonitrile 
AEX   anion exchange chromatography 
AU   arbitary unit 
BSA   bovine serum albumin 
BV   bed volume 
cDNA   coding DNA 
DMF  dimethylformamide 
DMSO  dimethylsufoxide 
dNTP  deoxynucleotide triphosphate 
dsDNA  double stranded DNA 
dsRNA  double stranded RNA 
DTT   dithiothreitol 
E. coli   Escherichia coli 
EC50  evective concentration 50 
EDC  
1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide 
Hydrochloride 
eEF2  eucaryotic elongation factor 2 
ELISA   enzyme linked immunosorbent assay 
EtBr  ethidium bromide 
EtOH  ethanol 
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FA   formic acid 
FITC  fluoresceinethiosemicarbazide 
FSC  forward sideward scatter 
GAPDH  glycerinaldehyd-3-phosphat-Dehydrogenase 
geo-MFI  geometric mean fluorescence intensity 
GFP  green fluorescent protein 
GMPS  guanosine-5’-O-monophosphothioate 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HRPO   horse radish peroxidase 
IgG  immunglobulin G 
IPTG  isopropyl-beta-D-thiogalactopyranoside 
Kan  kanamycin 
Kb  kilobase 
kDa  kilo-Dalton 
l  liter(s) 
LB  Luria broth 
M   molarity (mol/l) 
MAPK-1  mitogen activated protein kinase-1 
MFI  mean fluorescence intensity 
min  minute(s) 
miRNA  microRNA 
mmol  millimol 
mRNA  messenger RNA 
MS   mass spectrometry 
MW  molecular weight 
NBT-BCIP  nitro blue tetrazolium chloride/5-bromo 4-chloroindol-3- 
NHS  N-hydroxysuccinimide 
nm  nanometer 
nt  nucleotides 
NTP  nucleotide triphosphate 
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o/n   over night 
OD  optical density 
PA   phosphatidic acid 
PAGE  polyacrylamid gel electrophoresis  
PBS  phosphate buffered saline 
PCR   polymerase chain reaction 
PEG  polyethylene-glycol 
PI  phosphatidylinositol 
PI  propidium iodide 
pI   isoelectric point 
PSMA  prostate specific membrane antigen 
qPCR  quantitative real time RT-PCR 
RISC  rna induced silencing complex 
RNAi   RNA interference 
rpm  rounds per per minute 
RT  reverse transcription 
rt  room temperature 
scFv  single chain Fv 
SDS  sodium dofecylsulfate 
SELEX  selective evolution of ligands by exponential enrichment 
shRNA  short hairpin RNA 
siRNA  short interfering RNA 
SM  skim milk 
SMCC  
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-
carboxylate 
SPDP  N-succinimidyl-3-(2-pyridyldithio)propionate 
SPR  surface plasmon resonance 
ssDNA  single stranded DNA 
Taq  Thermus aquaticus 
TCEP  Tris(2-carboxyethyl)phosphine hydrochloride 
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UV   ultraviolet 
V   Volt 
v/v  volume per volume 
v/v  volume per volume 
w/v   weight per volume 
w/v   weight per volume 
XTT  
sodium 3’-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-
bis(4-methoxy-6-nitro)benzenesulfonic acid hydrate 
β-ME   β-mercaptoethanol 
μl  microliter 
μm   micrometer 
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